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The isolation of small molecule natural products from bacteria has led 
to the identification of many of the antibiotics currently in use today. Within 
the last 25 years, in fact, natural products (and their derivatives) account for 
almost three quarters of all antibiotic discoveries (Newman and Cragg). The 
discovery of novel natural product antibiotics, however, has witnessed a 
significant drop in numbers over this time period, suggesting that new 
sources of small molecules may be necessary to keep up with the need for new 
antibacterial compounds (Newman and Cragg). Due to the emergence of 
bacteria resistant to commonly used antibiotics, this need seems to be ever 
increasing, even as the pools of new antimicrobials are dwindling.  
One potential source of new small molecule diversity is the large 
quantity of uncultured bacteria found in any given environment. It is 
estimated that, in soil, greater than 99% of the bacteria present are 
recalcitrant to culture. This poses a challenge for the field of natural product 
discovery, considering the traditional route to small molecule discovery from 
soil bacteria is to organically extract pure cultures of an individual 
bacterium.  New techniques emerging from the field of metagenomics take a 
 culture-independent approach to examining the biosynthetic capabilities of 
soil bacteria by extracting the environmental DNA (eDNA) from the soil and 
cloning it into a host capable of maintaining and possibly heterologously 
expressing genes, which encode the production of small molecule secondary 
metabolites. These techniques have been employed in this thesis to expand 
not only a family of therapeutically relevant small molecule antibiotics 
(glycopeptides), but also to develop, in conjunction with new strategies, 
improvements on existing metagenomics approaches.  
My work towards the discovery of novel glycopeptide antibiotics has 
led to the identification of six novel glycopeptide biosynthetic pathways, via 
the use of homology-based metagenomics techniques, and the production of 
15 novel congeners of this extremely important family of compounds. 
Additional work in collaboration with members of the Darst Laboratory at 
the Rockefeller University led to the structural and biochemical 
characterization of two sulfotransferases, enzymes responsible for the 
sulfonation of a glycopeptide substrate. This type of chemical modification is 
rarely seen in glycopeptide biosynthesis, and the collection of three 
sulfotransferases identified using metagenomics techniques therefore 
presented a unique opportunity to gain a better understanding of the 
reactivity and substrate restrictions of these enzymes. 
In addition to the work using existing, homology-based metagenomics 
techniques, an additional strategy was developed, utilizing the 
 complementation of a well-studied biosynthetic pathway, responsible for the 
production of an iron-scavenging siderophore in E. coli, to select for eDNA 
clones likely to be rich in secondary metabolite biosynthetic genes. This 
strategy selects for clones containing 4’-phosphopantetheinyltransferases 
(PPtases), which are commonly proximally linked to the non-ribosomal 
peptide synthetases (NRPSs) and polyketide synthases (PKSs). PPtases are 
responsible for the post-translational modification of NRPSs and PKSs, which 
are genes commonly seen in secondary metabolite biosynthesis. This strategy 
was used to enrich an eDNA-derived metagenomic library for PKS and NRPS 
genes by over an order of magnitude compared to an unenriched library. 
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CHAPTER 1 
1 Introduction and Background 
1.1 Natural Products 
Over two thirds of the antibiotics discovered over the 25 year period 
spanning 1981-2006 are or are derived from small molecule natural products 
(Newman and Cragg 2007). Natural products fill many therapeutic niches, 
with properties ranging from antibacterial and anticancer agents to muscle 
relaxants and contraceptives. Soil bacteria have been a particularly prolific 
source of small molecule natural products. In fact, it is estimated that one 
bacterial genus alone, Streptomyces, has been the source of nearly two thirds 
of all clinically useful antibiotics (Kieser 2000). As there are predicted to be 
over 10,000 individual bacterial species per gram of soil, the reservoir for new 
bacterially-derived natural products seems rather promising.  
The isolation of small molecules from bacteria recovered from the 
environment has followed a largely unchanged pattern for decades. The 
traditional protocol used to isolate and identify natural products from 
bacteria is to first culture an individual bacterium from the environment, 
extract bacterial cultures using organic solvents, and isolate pure compounds 
through activity guided fractionation. Many of the compounds isolated using 
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this paradigm are not themselves essential to the growth of their bacterial 
progenitor. Although non-essential to growth, bacteria produce many of these 
compounds to gain a selective advantage in their natural environment. These 
molecules are collectively termed secondary metabolites and constitute the 
majority of bacterial natural products described to date.  
Secondary metabolites are used by bacteria for myriad of processes, 
including communication, self-defense, and iron scavenging (Maplestone, 
Stone et al. 1992). Bacterial secondary metabolites are often rather complex 
molecules that are generally produced via the transformation of simple 
starting materials by various groups of biosynthetic enzymes. These groups of 
enzymes, which are genomically encoded on either the bacterial chromosome 
or on stand-alone plasmids, are often clustered with one another into one or 
more functional operons. It is predicted that this clustering has facilitated the 
evolution of biosynthetic pathways capable of producing complex secondary 
metabolites (Maplestone, Stone et al. 1992). 
Although natural products have been a rich source of new chemistry, 
the discovery of new natural product antibiotics has declined over the last 
several decades (Fox 2006). The factors contributing to this decline are many 
and varied. The traditional culture-based paradigm itself, however, seems to 
be one of the major hurdles to new natural product isolation. As one would 
expect for any population subject to natural variation, there are bound to be 
both very common and very rare natural products. To identify the rarest 
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compounds from the milieu of known compounds may require a change in the 
paradigm, where one can examine all the bacteria in an environmental 
sample in an expeditious, facile, and unbiased manner.  Experimentation 
over the last several decades has indicated that the majority of the bacteria 
found in nature are not readily amenable to culture-based strategies 
(Torsvik, Goksoyr et al. 1990; Torsvik, Salte et al. 1990; Torsvik and Ovreas 
2002; Rappe and Giovannoni 2003). Thus, it is now apparent that the 
traditional culture-dependent paradigm has been omitting the vast majority 
of bacteria found in the biosphere.  
1.2 Uncultured Microbes 
Although the traditional culture-based strategy has proven very 
successful over the course of more than a century of investigation, it excludes 
a significant portion of the molecules present in most environmental samples. 
Culture-independent analyses of environmental samples suggest that 
traditional approaches used to identify microbial metabolites from laboratory 
grown microorganisms have likely missed the vast majority of bacterial 
natural products that exist in nature (Hugenholtz, Goebel et al. 1998; Rappe 
and Giovannoni 2003). In most environments, bacteria that have not yet been 
cultured are thought to outnumber their cultured counterparts by at least 
two orders of magnitude (Torsvik, Goksoyr et al. 1990; Hugenholtz, Goebel et 
al. 1998; Torsvik, Daae et al. 1998; Rappe and Giovannoni 2003). If the 
diversity of molecules discovered from cultured bacteria is any indication, as 
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yet uncultured bacteria are likely to be a very rewarding source of previously 
undiscovered biologically active small molecules.   
There are a number of different strategies, using both culture-
dependent and culture-independent methods, which are now being developed 
to access this untapped reservoir of chemical diversity. Typically, culture-
independent strategies involve direct cloning of the genetic material from an 
environmental sample, which contains the genes encoding for small molecule 
biosynthetic machinery. The genetic diversity of all the bacteria in any given 
environmental sample has been termed the “metagenome.”  Culture-
independent or “metagenomic” approaches can provide access to previously 
untapped pools of chemical diversity. It therefore seems likely that the pools 
opened up through metagenomics represent some of the largest reservoirs of 
unexamined genetic and chemical diversity remaining in nature. These types 
of culture-independent techniques are the basis of the research described in 
this thesis. 
1.3 Metagenomics 
The foundation of all metagenomic approaches is the isolation and 
subsequent examination of DNA extracted directly from naturally occurring 
microbial populations (environmental DNA, eDNA), which avoids the 
difficulties associated with culturing environmental bacteria (Figure 1) 
(Handelsman, Rondon et al. 1998). The collections of eDNA used for 
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metagenomic analyses contain vast quantities of genetic material, which 
undoubtedly possess the biosynthetic potential to produce a vast array of 
previously described secondary metabolites. To gain access to this 
biosynthetic machinery, one must first clone the eDNA into a suitable, 
cultured host, for archiving and subsequent downstream examination. One 
method of cloning often used in metagenomics is cosmid cloning, which takes 
advantage of the size selective packaging of lambda phage to transfect E. coli 
with environmental DNA clones containing between on average 40 kilobases 
of genetic material (Brady 2007). As previously mentioned, secondary 
metabolite biosynthetic gene clusters are often clustered in the bacterial 
genome. Metagenomics is particularly appealing to natural product 
researchers because of this characteristic clustering, since most secondary 
metabolite biosynthetic gene clusters are under 100 kb, making it possible to 
capture biosynthetic gene clusters on individual or, at most, a small number 
of overlapping eDNA clones (Handelsman, Rondon et al. 1998). Large scale 
cosmid cloning of environmental DNA provides a platform, from which one 
can investigate secondary metabolite biosynthetic gene clusters from 
uncultured bacteria.  
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Figure 1: Overview of metagenomic methods. 
Environmental DNA isolated directly from an environmental sample (1) is cloned into an 
easily cultured model bacterial host (2).  Libraries (or eDNA) can then be enriched for genes 
of interest (2a), transferred into additional heterologous hosts (2b), or screened directly.  The 
search for bioactive small molecules using a metagenomic approach has generally been 
conducted using either homology based methods (3a) or functional screening (3b).  Novel 
sequences found in homology-based screens (4a) can be examined for the ability to encode the 
biosynthesis of novel small molecules in heterologous expression experiments (5).  The 
characterization of hits from functional screens can lead directly to the identification of 
bioactive small molecules (4b) and their biosynthetic gene clusters (5). 
 
1.3.1 Functional metagenomic screening 
Expression-dependent (functional) metagenomic screening strategies 
have been used to identify eDNA clones that produce bioactive small 
molecules.  In functional metagenomic studies, eDNA libraries are examined 
in simple high throughput assays designed to identify clones that have 
phenotypes traditionally associated with the production of small molecules, 
such as pigmentation, altered colony morphology, or antibiosis. In homology-
based studies, libraries are probed to identify clones that contain conserved 
sequences traditionally associated with secondary metabolite biosynthesis.  
Next Generation Sequencing
1
2a 3a
3b
4a
4b
5
2b
2
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Hits identified in these initial high throughput assays are subsequently 
examined for the ability to confer the production of small molecules to model 
cultured heterologous hosts. 
One of the simplest strategies used to detect eDNA clones that might 
produce small molecule antibiotics has been to screen libraries hosted in E. 
coli for clones that generate zones of growth inhibition against test microbes 
in top agar overlay assays.  The isolation of clone specific metabolites 
produced by antibacterially active eDNA clones identified from bacterial top 
agar overlay assays has led to the characterization of a variety of new long-
chain N-acylated amines (1), as well as a new isonitrile functionalized indole 
antibiotic (2) (Figure 2) (Brady and Clardy 2000; Brady and Clardy 2005).  
Small molecule antibiotics have also been found by examining pigmented 
eDNA clones, as well as through the direct examination of culture broth 
extracts from randomly selected clones (Wang, Graziani et al. 2000; Brady, 
Chao et al. 2001; MacNeil, Tiong et al. 2001; Gillespie, Brady et al. 2002; 
Lim, Chung et al. 2005; Long, Dunlap et al. 2005).  Compounds with 
bioactivity identified from these types of studies include the antibiotic 
pigments violacein, indigo (3) and the turbomycins (4), all recovered from soil 
libraries, as well as the known cyclic peptides patellamide D (5) and 
nocardamine (6), isolated from marine sponge and soil libraries, respectively 
(Figure 2). 
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Figure 2:  Natural products heterologously produced in model cultured bacteria 
from metagenomic derived genes and gene clusters.   
N-acyltyrosine (1), isocyanide functionalized indole (2), indigo (3), turbomycin A (4), 
cyanobactin patellamide D (5), nocardamine (6) and psymberin (7). 
 
Functional metagenomics has also been used to identify clones that 
produce proteins with potential anti-infective properties.  Using an 
acylhomoserine lactone synthase promoter fused to a lacZ reporter, Schipper 
et al. identified three eDNA derived AHL lactonases that are capable of 
inhibiting biofilm formation by Pseudomonas aureginosa (Schipper, Hornung 
et al. 2009).  And, an examination of bacteriophage DNA isolated from bat 
guano and earthworm guts by Schmitz, et. al. led to the discovery of three 
new lysins capable of halting Bacillus anthracis proliferation (Schmitz, 
Daniel et al. 2008).  In this work, the authors were able to functionally access 
phage lysins by inducing the expression of genes cloned from environmental 
samples using a vector associated araBAD promoter. 
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Although nearly all small molecule focused functional metagenomic 
studies have been carried out in E. coli, it is likely that the majority of the 
biosynthetic diversity present in an environmental sample is not functionally 
accessible using a single heterologous host.  A computational analysis of 
promoters and ribosomal binding sites used by a taxonomically diverse group 
of sequenced bacteria found that at most, 40% of the enzymatic activities 
present within a typical metagenomic sample could be accessed using E. coli 
as a heterologous host (Gabor, Alkema et al. 2004).  The successful expression 
of entire biosynthetic gene clusters, which requires the coordinated 
production of multiple proteins, is likely to occur at an even lower frequency.  
Vector-host pairs that allow for the introduction and screening of 
metagenomic libraries in phylogenetically diverse bacteria have the potential 
to expand the number and type of compounds found from metagenomic 
studies.  While cosmid and BAC vectors capable of replicating in a variety of 
Gram-positive and Gram-negative hosts have been described in the 
literature, until recently, none of these had been used in an extensive broad-
host- range small molecule focused screen of metagenomic libraries (Courtois, 
Cappellano et al. 2003; Martinez, Kolvek et al. 2004). Two RK2-derived 
broad-host-range vectors (pJWC1 and pRS44) were recently constructed with 
this specific purpose in mind (Aakvik, Degnes et al. 2009; Craig, Chang et al. 
2009).  Craig, et al. demonstrated the utility of pJWC1 by screening 
metagenomic libraries for eDNA clones that confer antibacterial activities to 
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any of six different host Proteobacteria, including Agrobacterium tumefaciens, 
Burkholderia graminis, Caulobacter vibrioides, Escherichia coli, 
Pseudomonas putida, and Ralstonia metallidurans (Craig, Chang et al. 2009; 
Craig, Chang et al. 2010). This study found that distinct collections of eDNA 
clones within the same metagenomic library are likely to confer detectable 
phenotypes to different hosts and that eDNA clones infrequently confer the 
same phenotype to two different hosts. 
1.3.2 Metagenomic analysis of microbial endosymbionts 
Many bioactive natural products that were originally isolated from 
extracts derived from multicellular organisms are now thought to be products 
of as yet uncultured microbial symbionts.  Metagenomics provides a strategy 
for cloning the biosynthetic gene clusters of these metabolites, which may in 
turn provide a renewable source of compounds that have often been difficult 
to isolate in sufficient quantities to permit extensive biological testing. The 
biosynthetic gene cluster for pederin, an anticancer agent originally isolated 
from the beetle Paederus fuscipes, was recovered from a cosmid library 
constructed using beetle-derived metagenomic DNA and this pathway was 
shown to originate from an uncultured symbiotic Pseudomonas spp. (Soldati 
1966; Piel 2002). As additional pederin-like structures had also been isolated 
from marine sponge extracts, it was hypothesized that these other molecules 
might originate from bacterial symbionts as well.  In two separate studies, 
the Piel group reported the cloning of gene clusters encoding the biosynthesis 
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of the pederin relatives onnamide and psymberin (7) from symbionts 
associated with field collected Demospongiae sponges (Figure 2) (Piel, Hui et 
al. 2004; Fisch, Gurgui et al. 2009).  While it has not yet been possible to 
heterologously express these gene clusters in the laboratory, Zimmermann et 
al., reported the use of a recombinant O-methyltransferase, PedO, from the 
pederin biosynthetic gene cluster to site-specifically methylate mycalamide A 
resulting in the production of a derivative (8) that exhibits enhanced 
antitumor activity (Figure 3) (Zimmermann, Engeser et al. 2009).  In related 
work using libraries constructed from DNA extracted from uncultured 
cyanobacterial symbionts associated with marine Didemnidae sponges, two 
separate groups have reported the cloning and heterologous expression of 
biosynthetic gene clusters for a number of patellamides, cytotoxic cyclic 
peptides originally isolated from sponge extracts (Figures 2 and 3) (5,9) 
(Long, Dunlap et al. 2005; Schmidt, Nelson et al. 2005). 
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Figure 3: Secondary metabolites identified as a result of recent metagenomic 
efforts. 
O-methylated mycalamide A (8), patellamide A (9), erdacin (10), utahmycin A (11), fluostatin 
F (12), patellamides (13), and microviridins (14). The cyanobactin and microviridin precursor 
peptide diversity found in metagenomic studies is displayed on patellamide A and 
microviridin B, respectively. 
 
Most culture independent symbiont studies have focused on anticancer 
agents.  In future studies, the same general approach will undoubtedly prove 
useful for investigating symbiont-derived antimicrobials.  It was recently 
shown that a symbiotic Streptomyces species associated with leaf-cutting ants 
(Acromyrmex) produces the potent antifungal candicidin, which is active 
against the pathogenic fungus (Escovopsis), but non-active against the 
symbiotic fungus (Leucoagaricus) that the ants maintain as their main food 
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source (Haeder, Wirth et al. 2009).  While the producing organism in this 
study could be cultured, collections of uncultured microbial symbionts that 
promise to be rich sources of future small molecule metagenomic studies have 
been found in environments ranging from the human gut to marine snails 
(Peraud, Biggs et al. 2009; Qin, Li et al. 2010). 
1.3.3 Homology-based metagenomic screening 
Expression-independent or homology-based screens rely, as the name 
suggests, not on the expression of genes for detection of a small molecule as 
in functional metagenomics, but in the homology of previously unknown, 
eDNA-derived secondary metabolite biosynthetic pathways to sequenced 
pathways of known metabolites. One of the first groups of molecules targeted 
using this type of strategy was the iterative (Type II) polyketides (Seow, 
Meurer et al. 1997). Type II polyketides utilize a small collection of 
biosynthetic enzymes to produce a vast array of malonyl-CoA-derived 
scaffolds, which are modified and decorated by various downstream enzymes.  
This “minimal PKS,” two ketosynthase genes (KSα and KSβ) and an acyl 
carrier protein, possesses a conserved organization, and were therefore an 
ideal target to identify using homology-based metagenomic screening 
(Macpherson, Manning et al. 1994). Homology-based screening utilizes 
degenerate oligonucleotides to amplify sequence homologs via the polymerase 
chain reaction (PCR) (Seow, Meurer et al. 1997). Two reports had described 
the identification of type II PKS genes from environmental DNA samples, but 
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it was not until 2009 that a pathway encoding the biosynthesis of a type II 
PKS was expressed and a molecule characterized. This new molecule, erdacin 
(10) possesses a scaffold previously unseen in type II PKS biosynthesis, 
lending credence to the idea that uncultured bacteria may contain chemical 
diversity unlike that seen in cultured bacteria (Figure 3) (King, Bauer et al. 
2009). Since this study, several other studies have been published, detailing 
the discovery of additional novel type II PKS-derived compounds, such as 
utahmycin A (11) and fluostatin F (12) (Figure 3) (Bauer, King et al. 2010; 
Feng, Kim et al. 2010). Taken together, these reports offer a glimpse of the 
previously unseen chemistry homology-based metagenomic screening has the 
potential to uncover. 
In an expansion of its earlier cyanobactin (patellamide) research 
(Schmidt, Nelson et al. 2005), the Schmidt group recently reported the PCR 
amplification of 30 genes encoding novel patellamide-like precursor peptides 
from uncultured Prochloron spp. symbionts living in consortia with marine 
sponges (13) (Figure 3) (Donia, Hathaway et al. 2006; Schmidt and Donia 
2009). In another PCR based study, in this case using DNA isolated from 
uncultured freshwater cyanobacteria of the genera Microcystis, Ziemert, et al. 
identified 15 new variants of the gene that encode for the precursor to the 
microviridin peptide (14) (Figure 3) (Ziemert, Ishida et al. 2010). 
Microviridins are ribosomally synthesized tricyclic depsipeptide proteases 
inhibitors produced by a number of cyanobacteria. The discovery of both the 
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new microviridin and patellamide-like precursor peptides should aid in 
attempts to generate additional members of these two important cyclic 
peptide families.   
Most homology-based screens have been carried out using degenerate 
PCR primers designed to recognize conserved sequences within secondary 
metabolite biosynthetic genes.  As more metagenomic sequencing data 
appears in publicly available databases, it should also be possible to use 
purely bioinformatics based search strategies to identify new natural product 
biosynthetic enzymes and gene clusters.  An in silico examination of data 
from the Global Ocean Metagenomic Survey for genes involved in the 
biosynthesis of lantibiotic type antibiotics uncovered more than 20 novel 
lantibiotic cyclases (Li, Sher et al. 2010).  This class of peptide cyclase is used 
in the biosynthesis of potent cyclic peptide antibiotics (lantibiotics) from short 
linear ribosomally synthesized peptides.  Environmental DNA derived 
lantibiotic cyclases could one day aid in the enzymatic synthesis of new 
lantibiotic variants.  The examination of eDNA libraries and metagenomic 
sequencing data for relatives of known biosynthetic systems is likely to be a 
generally applicable strategy for identifying new structural variants of many 
bacterially derived antibiotics, potentially providing ready access to 
compounds with improved pharmacological properties and improved spectra 
of activity. 
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1.4 Library Enrichment Strategies 
The development of generic gene enrichment strategies would 
undoubtedly simplify the screening of large eDNA libraries and likely 
increase the utility of metagenomics as a tool for the discovery of novel 
bioactive small molecules.  A number of DNA hybridization strategies, 
including subtractive hybridization, PCR denaturing gradient gel 
electrophoresis (PCR-DGGE), "biopanning" and fluorescence in-situ 
hybridization coupled with cell sorting have been explored for enriching 
eDNA samples for genes of interests with varying degrees of success (Gray, 
Richardson et al. 2003; Kalyuzhnaya, Zabinsky et al. 2006; Quinton, 
Stephanie et al. 2007; Chew and Holmes 2009; Morimoto and Fujii 2009).  
Zhang, et al. recently reported a phage display-based strategy for specifically 
enriching eDNA libraries for clones containing two important classes of 
natural product biosynthetic genes, polyketide synthases and non-ribosomal 
peptide synthetases (NRPS) (Zhang, He et al. 2009).  Their selection strategy 
takes advantage of the fact that PKS and NRPS proteins are 
posttranslationally modified with the addition of a phosphopantetheine 
prosthetic group.  Phage that display either PKS or NRPS proteins on their 
surface could therefore be collected by first incubating the phage library with 
a recombinant phosphopantetheinyltransferase and a biotinylated 
phosphopantetheine analog, and then panning with streptavidin.  At the 
moment, complete biosynthetic gene clusters are not accessible using this 
17 
 
strategy.  It does, however, provide a promising method for recovering 
individual NPRS and PKS megasynthases from complex eDNA samples.  
18 
 
CHAPTER 2 
2 Homology-based metagenomic efforts towards the 
production of novel glycopeptide antibiotics 
2.1 Chapter Summary 
Homology-based metagenomics efforts have the potential to identify 
novel biosynthetic pathways related to any previously sequenced biosynthetic 
gene cluster. This chapter details the application of homology-based 
metagenomics to the identification of novel glycopeptide antibiotic 
biosynthetic gene clusters from three eDNA-derived cosmid mega-libraries. 
Using degenerate oligonucleotides designed to specifically target a 
biosynthetic enzyme unique to glycopeptide biosynthesis, oxyC, a preliminary 
screen was carried out to assess the prevalence of oxyC in a range of eDNA 
samples from varied geographic locations. This screen, which used 11 eDNA 
samples from three different continents as PCR template, discovered oxyC 
homologs in every sample examined.  
After the preliminary screen, three eDNA cosmid mega-libraries, each 
containing in excess of ten million unique members, were screened using the 
same degenerate PCR primers from the preliminary screen. This screen led 
to the identification, recovery, and sequencing of six novel glycopeptide 
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biosynthetic pathways. These pathways were subsequently used to produce 
fifteen novel glycopeptide congeners, through a combination of in vitro and in 
vivo techniques. These compounds maintained their antibiotic activity 
against Staphylococcus aureus and Enterococcus faecalis in antibacterial test 
assays. 
2.2 Introduction 
Glycopeptide antibiotics are soil-bacterially derived secondary 
metabolites, which display potent bacteriostatic activity against a range of 
Gram-positive bacteria. Two of the most commonly employed glycopeptides, 
vancomycin (15) and teicoplanin (16), are widely used to treat nosocomial 
Gram-positive bacterial infections in humans (Figure 4). More recently, 
vancomycin has been quite heavily administered to treat the emergence of 
Staphylococcus aureus, which displays resistance to the more commonly used 
beta-lactam antibiotics (methicillin-resistance S.aureus, MRSA). However, 
the emergence of strains of S. aureus and Enterococci resitant to vancomycin 
(vancomycin-resistant S. aureus, VRSA and vancomycin-resistant 
Enterococci, VRE, respectively) threaten to render glycopeptides obsolete. 
Recent efforts in glycopeptide discovery have focused primarily on semi-
synthetic efforts, as the identification of novel glycopeptide congeners from 
soil bacteria has waned over the last few decades. 
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Figure 4: Vancomycin (15) and teicoplanin (16) 
 
There are over 150 known glycopeptides isolated from bacterial 
cultures, yet there are only four different heptapeptide scaffolds seen in 
glycopeptide biosynthesis. These scaffolds are initially biosynthesized by non-
ribosomal peptide synthetases (NRPS), large, multimodular enzymes, which 
produce linear peptides. The sequence of the peptide produced by the NRPS 
is determined by the amino acid sequence of the NRPS itself (Stachelhaus, 
Mootz et al. 1999). Glycopeptides often contain pathway encoded, non-
canonical amino acids, such as β-hydroxytyrosine (17), 4-
hydroxyphenylglycine (18), or 3,5-dihydroxyphenylglycine (19) (Figure 5). 
These linear heptapeptides are subsequently oxidatively cross-linked, to form 
either three or four macrocycles. The majority of glycopeptide diversity is 
provided by an extensive repertoire of tailoring enzymes, which site-
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specifically perform an array of biosynthetic modifications, including, but not 
limited to, glycosylation, acylation, methylation, and sulfonation. This 
chapter describes the homology-based metagenomics search for novel 
glycopeptide biosynthetic gene clusters, and the subsequent use of enzymes 
found in these clusters to produce novel glycopeptide congeners both in vitro 
and in vivo. 
 
Figure 5: Non-canonical amino acids common in glycopeptide biosynthesis. 
β-hydroxytyrosine (BHT) (17), hydroxyphenylglycine (HPG) (18), and di-
hydroxyphenylglycine (DPG) (19). 
 
2.3 Results 
2.3.1 Crude eDNA Screening and eDNA-derived Cosmid Mega-
Library Construction 
 To identify potentially novel glycopeptide biosynthetic gene clusters 
from environmental samples using a homology-based metagenomics approach 
first required identification of a gene unique to glycopeptide biosynthesis, 
that would limit background while not excluding possible pathway hits. The 
selected target gene encodes the production of an oxidative enzyme, whose 
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activity is responsible for the direct C-C coupling of the HPG at position 5 
and the DPG at position 7 during macrocycle formation in heptapeptide 
maturation (Figure 6). This gene, oxyC, is common to all sequenced 
glycopeptide biosynthetic gene clusters. Importantly, all known oxyC genes 
display greater than 75% DNA sequence homology to each other, yet are 
easily distinguishable from genes encoding other oxidative enzymes. This 
high level of homology allowed for the design of degenerate oligonucleotides 
to specificaly target oxyC using a PCR based screen.  
 
Figure 6: A possible mechanism for the C-C coupling reaction performed by the 
P450 mono-oxygenase oxyC 
 
The first investigation using these PCR probes was carried out on a 
group of geographically diverse, crude eDNA samples. These samples were 
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collected from several locations in Africa, Central America, and North 
America. Nested primers were designed to specifically target these genes in 
these extremely complex mixtures. These primers identified novel oxyC-like 
genes in every sample examined (Figure 7). However, it would take a 
significant increase in the efficiency of eDNA cosmid cloning to transition 
from the amplification of gene segments to the recovery of intact glycopeptide 
gene clusters. 
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Figure 7: Phylogenetic tree of oxyC amplicons identified from crude eDNA samples 
Phylogenetic tree of oxyC amplicons amplified from crude eDNA samples. Trimmed 
sequences for several known oxyC genes are also included for comparison, as well as an 
oxidative enzyme from the biosynthesis of a compound closely related to glycopeptides, 
complestatin for an outgroup.  
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It was hypothesized that if a large enough collection of eDNA clones 
could be constructed from a single environmental sample, complete 
glycopeptide biosynthetic gene clusters could be identified on overlapping 
clones, and recovered for sequencing. However, at that time, the largest 
eDNA-derived cosmid libraries were comprised of at most several thousand 
clones (Courtois, Cappellano et al. 2003). It was elsewhere determined that 
seqeunce redundancy was not observed until a cosmid library contained in 
excess of one million clones (Kim, Feng et al. 2010). Glycopeptide biosynthetic 
gene clusters are generally in excess of 70,000 bp, which would require 
multiple overlapping cosmid clones to recover in totality. The recovery of 
intact glycopeptide biosynthetic gene clusters would require a library several 
orders of magnitude larger than those previously constructed. Through trial 
and error, it was determined that the eDNA purified from samples, which are 
much less rich in organic matter, e.g. desert soils displays a much higher 
cloning efficiency than soils very rich in organic matter, e.g. soil from a 
deciduous forest. This discovery led to the construction of multiple eDNA-
derived cosmid “mega-libraries,” which each contained in excess of ten million 
individual clones, the equivalent of 100,000 4-mb bacterial genomes. 
 To aid in screening, each library was constructed as a collection of 
5,000 clone sublibrary pools. Each library contained in excess of 2,000 of 
these sublibraries, which were arrayed into 8x8 grids, again to aid in library 
screening. Each 8x8 grid was pooled in two ways: all sixty-four sublibraries in 
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one aliquot, termed the “grand pool” and all eight sublibraries in one row 
pooled in one aliquot. PCR screening proceeded through an initial screen of 
all grand pools. A hit in a grand pool, identified by PCR screening and 
subsequent amplicon seqeuencing, led to subsequent screening of the 
pertinent rows of pooled sublibraries, followed by screening of the eight 
individual sublibraries. Once a single sublibrary was identified as containing 
a clone of interest, that sublibrary was serially diluted over several rounds to 
isolate one individual clone from the entire sublibrary aliquot of over 5,000 
clones.  
2.3.2 eDNA-derived Cosmid Mega-Library Screening and 
Glycopeptide Biosynthetic Gene Cluster Recovery 
 Using the same oxyC-based degenerate primers, PCR screening was 
carried out on all of the grand pools from each of three cosmid mega-libraries, 
one constructed from soil collected from a desert in Utah (UT), one 
constructed from soil collected from the Anza-Borrego desert in California 
(AB), and a third library constructed from soil collected from a desert in 
Arizona (AZ). The screening of the UT cosmid mega-library led to the 
identification of two oxyC-like hits (UTA15 and UTD30). These eDNA-derived 
hits were then added to the previously known sequences to design a second 
set of degenerate PCR primers. The screening of the AB and AZ libraries with 
both sets of degenerate primers led to the identification of three oxyC-like 
hits in the AB library (AB37, AB878, and AB915) and one oxyC-like hit in the 
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AZ library (AZ205). The cosmid clones containing these oxyC-like sequences 
were recovered and sequenced using 454 pyrosequencing (Roche). A 
phylogenetic analysis of the full-length oxyC sequences from these recovered 
clones revealed that the oxyC sequences recovered using culture-independent 
methods appeared as diverse as those recovered from cultured bacteria 
(Figure 8). 
 
Figure 8: Phylogenetic analysis of sequenced oxyC genes  
oxyC sequences identified from cultured bacteria (from the A40926, A47934, Balhimycin, 
Teicoplanin, and Vancomycin biosynthetic gene clusters) and uncultured bacteria (from the 
UT, AB, and AZ eDNA-derived cosmid mega-libraries). Again, an oxidative enzyme from the 
pathway encoding a compound related to glycopeptides, complestatin, has been included as 
an outgroup.  
 
Complestatin
A40926
AB878
AZ205
UTA15
Vancomycin
Balhimycin
UTD30
AB37
Teicoplanin
AB915
A47934
50.0
28 
 
 
Upon successful recovery and sequencing of the eDNA clones 
containing oxyC genes, new primers, specific to the ends of the eDNA insert 
for each cosmid clone containing glycopeptide biosynthetic machinery, were 
designed to identify and recover overlapping clones to recover and sequence 
entire gene clusters. This process of recovery and sequencing was repeated 
until the pathway was predicted to be complete, or no overlapping clone could 
be found.  
2.3.3 Glycopeptide Pathway Annotation and Sequence Analysis 
It was predicted that five of the six glycopeptide pathways identified in 
these megalibrary screens are complete, with one, the UTD30 pathway, being 
truncated due to the absence of overlapping clones in the UT mega-library. 
The UT library was the first library screened using the degenerate oxyC 
specific primers. Of the two oxyC sequences found in the UT library, one 
(UTA15) is more closely related to those found in sequenced vancomycin-like 
gene clusters (vancomycin-like eDNA derived gene cluster, VEG cluster), 
whereas the other (UTD30) resembles those found in sequenced teicoplanin-
like gene clusters (teicoplanin-like eDNA derived gene cluster, TEG cluster). 
Cosmids containing the more common VEG pathway appeared in 
approximately 1 of every two million clones, whereas clones containing the 
less common TEG pathway were found in one of every 5–10 million clones. 
For the common pathway, ~100 kb of continuous sequence were 
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reconstructed from 6 overlapping cosmid clones. Almost 75 kb of this 
sequence are predicted to be part of a glycopeptide antibiotic biosynthetic 
gene cluster. For the less common TEG pathway, ~50 kb of continuous 
sequence were reconstructed from three overlapping cosmid clones. Although 
the TEG gene cluster is truncated at one end, a comparison of the two gene 
clusters, which are closely related at both ends but differ significantly in the 
central finishing enzyme regions, suggests that the missing region is likely to 
contain conserved biosynthetic machinery that is common to most 
glycopeptide gene clusters. 
The clusters found in the AB and AZ clusters were well represented in 
these mega-libraries, which aided significantly in the complete recovery of all 
pathways. After full sequencing and annotation, each set of overlapping 
cosmid clones could be assembled into a single 100-120 kb contig that 
appears to contain a full glycopeptide biosynthetic gene cluster (Figure 9) All 
three gene clusters recovered from the AB library and the one gene cluster 
recovered from the AZ library are predicted to contain a complete 
complement of glycopeptide biosynthetic genes and show the same conserved 
gene cluster architecture that is seen in most previously sequenced 
glycopepetide gene clusters (Figure 9). Detailed description of all ORFs in the 
six eDNA-derived glycopeptide gene clusters are provided in the Appendix 
(Tables 7-12). 
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Figure 9: Annotated glycopeptide biosynthetic gene clusters  
A) Annotated pathways for select glycopeptides originally isolated from cultured soil 
bacteria. B) Six glycopeptide clusters that were recovered as a part of the work detailed in 
this thesis using culture-independent methods 
 
NRPS modules are predicted to carry out a single condensation 
reaction that extends the growing peptide by one amino acid (Marahiel, 
Stachelhaus et al. 1997) At a minimum, a module contains a condensation 
domain for condensing an incoming amino acid with the growing peptide, an 
adenylation domain for selecting and activating the incoming amino acid and 
a thiolation domain that carries the growing peptide.  The amino acid 
incorporated by a module is determined by a small number of variable 
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residues found in the adenylation domain (Table 1) (Stachelhaus, Mootz et al. 
1999). Table 1 shows these key amino acid specificity residues from each 
adenylation domain found in the six eDNA-derived glycopeptide biosynthetic 
pathways. 
A detailed analysis of the six eDNA derived gene clusters indicates 
that each is predicted to encode the biosynthesis of a previously unknown 
glycopeptide congener.  As expected, all clusters contain large NRPS systems 
that are predicted to encode heptapeptides (Figure 9).  The NRPS system in 
the VEG pathway is predicted to encode the biosynthesis of a Type II 
heptapeptide, HPG-BHT/TYR-HPG-HPG-HPG-BHT/TYR-DPG, with only 
three predicted macrocyclizations and the TEG pathway is predicted to 
encode the biosynthesis of a Type III heptapeptide HPG-BHT/TYR-HPG-
HPG-HPG-BHT/TYR-DPG with four predicted oxidative macrocyclizations 
(Table 1). Similary, based on a comparison of these residues to those seen in 
adenylation domains from sequenced glycopeptide NRPS modules, all three 
AB gene clusters are expected to encode the production of a Type III HPG-
BHT/TYR-HPG-HPG-HPG-BHT/TYR-DPG-like heptapeptide (Table 1). The 
pathway recovered from the AZ library is simlar to the VEG pathway, with a 
predicted Type II, HPG-BHT/TYR-HPG-HPG-HPG-BHT/TYR-DPG backbone 
with only three predicted oxidative macrocyclizations. Potential ambiguities 
in the predicted peptide arise from the mode of BHT incorporation, which has 
been reported to occur by two distinct mechanisms during glycopeptide 
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biosynthesis.  BHT can be biosynthesized and incorporated directly into the 
glycopeptide backbone through BHT-specific adenylation domains, or it can 
be produced by oxidizing tyrosine in a reaction that takes place after the 
selective incorporation of tyrosine into the growing peptide (Puk, Bischoff et 
al. 2004; Stinchi, Carrano et al. 2006). Both AB37 and AB915 are predicted to 
generate BHT through the latter, tyrosine-oxidation strategy.  NRPS 
modules 2 and 6 from both gene clusters are predicted to incorporate TYR 
into the growing peptide.  However, as can be seen in a similar analysis of 
both the teicoplanin and A47934 NRPS modules, the final residues at these 
positions will be BHT if the tyrosines are subsequently oxidized.  
Table 1: NRPS adenylation domain predictions 
(* indicates possible side of ambiguity, based on biosynthesis of BHT and TYR)  
 Binding Pocket Substrate Prediction 
TEG Pathway   
Module 1 DAFSLGLL DAFLLGLL (A47934-M1-HPG) 
Module 2 DTSKVAAI DTSKVAAI (Cep-M2-BHT)* 
Module 3 DPFFQGTF DPYLGGT (Cep-M7-DPG) 
Module 4 DIFLLGLL DIFHLGLL (Cep-M4-HPG) 
Module 5 DALLLGLL DAVHLGLL (Cep-M5-HPG) 
Module 6 DASTLGAI DASTLGAI (Cep-M6-BHT)* 
Module 7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
   
VEG Pathway   
Module 1 DAFTLGLL DAFLLGLL (Tcp-M1-HPG) 
Module 2 DTSKVAAI DTSKVAAI (Cep-M2-BHT)* 
Module 3 DAFSLGLL DIFHLGLL (Cep-M4-HPG) 
Module 4 DIFLLGLL DIFHLGLL (Cep-M4-HPG) 
Module 5 DAVLLGIG DIFHLGLL (Cep-M4-HPG) 
Module 6 DASTLGAI DASTLGAI (Cep-M6-BHT)* 
Module 7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
   
AB 37 Pathway   
Module1 DAFLLGLL DAFLLGLL (Tcp-M1-HPG) 
Module2 DASTVAAV DASTVAAV (A47934-M2-TYR)* 
Module3 DAYFSGSL DAYFLGTL (Tcp-M3-DPG) 
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Module4 DIFTLGLL DIFHLGLL (Cep-M4-HPG) 
Module5 DALLLGLL DALLLGVG (Tcp-M5-HPG) 
Module6 DASTVAAV DASTVAAV (A47394-M2-TYR)* 
Module7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
   
AB 878 Pathway   
Module1 DAFNLGLL DAFLLGLL (Tcp-M1-HPG) 
Module2 DTSKVAAI DTSKVAAI (Cep-M2-BHT)* 
Module3 DAYFQGTF DAYFLGTL (Tcp-M3-DPG) 
Module4 DIFTLGLL DIFHLGLL (Cep-M4-HPG) 
Module5 DAVLLGLL DAVHLGLL (Cep-M5-HPG) 
Module6 DASTLGAI DASTLGAI (Balhi-M6-BHT)* 
Module7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
   
AB 915 Pathway   
Module1 DAFSLGLL DAFLLGLL (Tcp-M1-HPG) 
Module2 DASTVAAV DASTVAAV (A47934-M2-TYR)* 
Module3 DAFFSGSL DAFLLGLL (A47934-M1-HPG) 
Module4 DIFLLGLL DIFHLGLL (Cep-M4-HPG) 
Module5 DALLLGLL DALLLGVG (Tcp-M5-HPG) 
Module6 DASTIAAV DASTIAGV (Tcp-M6-BHT)* 
Module7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
   
AZ 205 Pathway   
Module1 DAFGQGLV DAFLLGLL (Tcp-M1-HPG) 
Module2 DASTVAAV DASTVAAV (A47934-M2-TYR)* 
Module3 DVLLVGTI DALLLGVG (Tcp-M5-HPG) 
Module4 DIFTLGLL DIFHLGLL (Cep-M4-HPG) 
Module5 DALLLGLL DAFLLGLL (Tcp-M1-HPG) 
Module6 DASTLGAI DASTLGAI (Balhi-M6-BHT)* 
Module7 DPYLGGTL DPYLGGTL (Cep-M7-DPG) 
 
The VEG cluster contains a complete complement of the genes 
predicted to be necessary for the biosynthesis of an oxidatively cross-linked 
heptapeptide.  This includes all of the biosynthetic machinery required for 
the production of the three non-canonical amino acids (HPG, BHT and DPG) 
found in the peptide core, a halogenase for the production of chloro-BHT, and 
the three oxidative enzymes that oxidatively cross-link the heptapeptide core 
(Figure 9) (Choroba 2000; Hubbard, Thomas et al. 2000; Chen, Tseng et al. 
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2001; Puk, Bischoff et al. 2004; Sosio, Kloosterman et al. 2004; Stinchi, 
Carrano et al. 2006; Sri, Ellen et al. 2009). In addition to the core 
biosynthetic machinery, the VEG cluster contains seven glycosyltransferases 
and three methyltransferases.  Two of the three methyltransferases are 
predicted N-methyltransferases suggesting that the product of the VEG 
pathway is doubly N-methylated at the N-terminus.  
Four of the glycosyltransferases in the VEG gene cluster are related to 
glycosyltransferases from chloroeremomycin biosynthesis, two are related to 
putative mannosyltransferases from teicoplanin-like biosynthetic gene 
clusters, and the seventh is related to the glycosyltransferase CalG1 from 
calicheamycin biosynthesis.  Two of the related glycosyltransferases from 
chloroeremomycin biosynthesis use derivatives of vancosamine as substrates.  
Homologs of the five enzymes required for the biosynthesis of a vancosamine 
derivative are also found in the VEG gene cluster (Figure 9) (Chen, Thomas 
et al. 2000). To the best of our knowledge, no glycopeptide congener 
containing the unique assortment of functionality encoded by the VEG gene 
cluster (doubly N-methylated, vancosamine functionalized, Type II 
glycopeptide) has been characterized from cultured bacteria. 
While the VEG gene cluster is rich in methyl- and 
glycosyltransferases, the TEG gene cluster is rich in sulfotransferases (Figure 
9).  In addition to containing biosynthetic machinery that is required for the 
production of an oxidatively crosslinked heptapeptide core, the TEG gene 
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cluster contains three predicted sulfotransferases. Although a large number 
of glycosylated, halogenated, and alkylated glycopeptide congeners have been 
identified from studying cultured bacteria, only two sulfated, and no 
polysulfated, glycopeptides have been reported (Boeck and Mertz 1986; 
Holdom 1988). The presence of three sulfotransferases in the TEG cluster 
suggested that it was likely to encode the biosynthesis of the first 
polysulfated glycopeptides.   
The AB37 and AB915 gene clusters each contain genes encoding four 
glycosyltransferases, a mannosyltransferase, a halogenase, and three 
methyltransferases (Figure 9).  Both gene clusters also contain genes 
encoding enzymes used in the biosynthesis of a number of different rare 
glycopeptide-associated sugars, including vancosamine, acosamine or 
ristosamine (Debono, Merkel et al. 1984; Heald, Mueller et al. 1987; Chen, 
Thomas et al. 2000). It is not possible from the DNA sequence alone to tell 
which of these sugars the two gene clusters will actually produce.  Of the 
known glycopeptide congeners that contain five sugars, only actaplanin 
contains the same cross-linked heptapeptide that is predicted to arise from 
the AB37 and AB915 gene clusters (Debono, Merkel et al. 1984). These gene 
clusters may therefore encode the biosynthesis of actaplanin itself or more 
highly glycosylated and methylated actaplanin-like glycopeptides. 
The AB878 gene cluster contains genes encoding four 
glycosyltransferases, two mannosyltransferases, a halogenase, and two 
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methyltransferases.  This gene cluster also contains homologs of the same 
sugar biosynthetic genes that are seen in AB37 and AB915.  Based on the 
collection of tailoring enzyme genes present in AB878, this gene cluster would 
appear to encode the biosynthesis of a ristocetin-like congener.  Ristocetin 
contains the same heptapeptide as is predicted to arise from the AB878 gene 
cluster as well as six sugars, including a ristosamine, and two methyl 
substituents (Fehlner, Hutchinson et al. 1972). The presence of a halogenase 
in AB878 suggests that this cluster probably does not produce ristocetin 
itself, but instead produces a halogenated ristocetin-like congener.  
The AZ205 cluster is a mixture of the methyl/glycosyl-transferase rich 
(VEG/AB37/AB878/AB915) pathways and the sulfotransferase-rich (TEG) 
pathway. It possesses all of the required resistance elements, NRPS genes, 
and substrate biosynthetic machinery, as well as a predicted N-
methyltransferase, glycosyltransferase, and sulfotransferase. The predicted 
product of this pathway, an N-methylated, glycosylated, sulfonated type III 
glycopeptide, is different from any previously reported glycopeptide congener.  
For sequenced gene clusters, the number and type of tailoring enzymes 
found in these clusters is a reliable predictor of the features that are seen in 
the most highly functionalized congener it produces (Figure 10) (Goldstein, 
Selva et al. 1987; van Wageningen, Kirkpatrick et al. 1998; Pelzer, Sussmuth 
et al. 1999; Pootoolal, Thomas et al. 2002; Sosio, Kloosterman et al. 2004). 
The inventory of tailoring enzymes found in cryptic eDNA-derived 
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glycopeptide gene clusters should in turn be a reasonable predictor of the 
features found in the congeners produced by these gene clusters.  This type of 
analysis does not allow for precise structural predictions to be made because 
it does not account for differences in regioselectivity, subtle differences in 
substrate specificities or the functional order of the tailoring enzymes.  It can, 
however, provide an indication as to whether or not a cryptic gene cluster has 
the potential to generate a glycopeptide congener with a unique number or 
type of prosthetic groups.  
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Figure 10: NRPS and Tailoring Enzyme Inventory 
An inventory of the number and type of tailoring enzymes (or functional group transferases) 
found in sequenced gene clusters from cultured soil bacteria as well as gene clusters cloned 
from eDNA, is shown. For gene clusters associated with known metabolites, the number of 
tailoring-enzyme-derived functional groups found on the encoded metabolite is also shown  
 
A similar detailed accounting of the enzymes in each of the eDNA-
derived glycopeptide biosynthetic gene clusters allowed for a comparison of 
the predicted structures to known glycopeptide congeners (Figure 10). In 
addition to the seven NRPS modules that are predicted to produce the 
heptapeptide, each gene cluster encodes three (or four) predicted 
monooxygenases that are homologs of OxyA-C (or A-D) (Figure 9).  OxyA-D 
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AZ205 B H or OH H or OH 1 0 2 1 1 0 1 
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catalyze the four oxidative couplings that are needed to generate the four 
macrocycles seen in many glycopeptides (Pootoolal, Thomas et al. 2002).  
2.3.4 Novel Glycopeptide Congener Production  
The collection of novel sulfotransferases identified in the TEG pathway 
provided an opportunity to rapidly produce a considerable collection of 
glycopeptide congeners. The substrate upon which these sulfotransferases act 
was predicted based on the complete sequence of the NRPS genes recovered 
as part of the TEG pathway to be either the teicoplanin aglycone or the 
dehydroxylated teicoplanin aglycone. The teicoplanin aglycone is readily 
available and therefore we elected to use this substrate in in vitro studies 
with the TEG sulfotransferases.  The three sulfotransferases (Teg12, 13, and 
14) in the TEG cluster are homologs of StaL, a 3'-phosphoadenosine 5'-
phosphosulfate (PAPS) dependent sulfotransferase found in the A47934 
glycopeptide gene cluster (Pootoolal, Thomas et al. 2002). StaL has been used 
to generate monosulfonated glycopeptides in vitro (Lamb, Patel et al. 2006). 
For our in vitro glycopeptide sulfonation studies TEG12, 13, and 14) were 
PCR amplified and cloned into the pET28a expression vector.  Each 
recombinant 6-HIS-tagged sulfotransferase was then Ni-affinity purified 
from cultures of E. coli BL21(DE3).  In the presence of PAPS and the 
teicoplanin aglycone each predicted sulfotransferase produces a unique 
monosulfonated glycopeptide derivative, sulfo-teicoplanin aglycones A-C (20-
22)(Figure 11).  In reactions with two sulfotransferases, the three possible 
40 
 
disulfonated derivatives are formed  (sulfo-teicoplanin aglycones D-F (23-25)), 
and in a reaction with all three sulfotransferases a tri-substituted derivative 
is produced, sulfo-teicoplanin aglycone G (26) (Figure 11).  
Figure 11: New sulfonated glycopeptide derivatives produced using combinations 
of in vivo and in vitro methods using eDNA-derived tailoring enzymes 
 
Mass spectrometry and 1 and 2D NMR were used to identify the 
sulfonation site in each monosulfonated product (Figures 20-31 in the 
Appendix) The sulfonation patterns seen in the di- and tri- sulfonated 
teicoplanin aglycone analogs were then inferred from the sulfonation 
specificities of the sulfotransferases used to synthesize these derivatives.  
Upon fragmentation by negative ion ESI-MS/MS, each of the monosulfonated 
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33 H SO3H H Cl CH3 H SO3H A47934 + AZ205 Sulf 
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aglycone derivatives produces a daughter ion with an m/z=906. This 
fragment, which is not produced by the teicoplainin aglycone (Figure 29 in 
the Appendix), corresponds to a sulfonated product that has lost the 
macrocycle formed by amino acids five and seven. The presence of this 
sulfonated fragment eliminates three of the seven hydroxyls on the 
teicoplainin aglycone as candidates for sulfonation.  To determine which of 
the four remaining hydroxyls are sulfonated, HPLC purified sulfo-teicoplanin 
aglycones, derived from milligram scale sulfonation reactions, were analyzed 
by 1 and 2D NMR, and these spectra were compared to those obtained with 
the teicoplanin aglycone (Tables 13-16 in the Appendix) (Malabarba, Ferrari 
et al. 1986; Boger, Weng et al. 2000). Compared to their hydroxylated 
counterparts, sulfonated compounds show significant deshielding (~0.5 ppm) 
of aromatic protons ortho to the site of sulfonation as well as deshielding of 
aliphatic protons that are attached to a sulfonated carbon. (Boeck and Mertz 
1986; Pretsch, Bühlmann et al. 2000; Yates, Santini et al. 2000)  Sulfonation 
of the hydroxyls on the amino acids at positions three, six and four by TEG12, 
13, and 14 respectively, could be inferred from the sulfate induced 
deshielding of protons present in the 1H NMR spectra of sulfo-teicoplanin 
aglycones A, B and C (Figures 19, 24, and 27, respectively in the Appendix).  
In sulfo-teicoplanin aglycone A (the TEG12 product), the two protons ortho to 
the hydroxyl on the resorcinol side chain of amino acid three are deshielded 
by 0.51 and 0.57 ppm relative to their chemical shifts in the aglycone.  In 
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sulfo-teicoplanin aglycone B (the TEG13 product), the beta carbon proton of 
amino acid six is deshielded by 0.59 ppm relative to the aglycone.  In sulfo-
teicoplanin aglycone C (the TEG14 product), no protons ortho to a potential 
sulfonation site are significantly deshielded compared to the aglycone.  The 
hydroxyphenylglycine at position four is the only potential sulfation site that 
is not predicted to undergo significant proton chemical shifts changes upon 
sulfonation.  The cup shaped conformation of glycopeptides places a sulfate at 
position four in close proximity to the protons on amino acid two, which could 
explain the 0.43 ppm deshielding of the proton meta to the chlorine on amino 
acid two in sulfo-teicoplanin aglycone C.  After literature examination, it is 
believed that all three sites sulfonated by the TEG sulfotransferases differ 
from those sulfonated in known glycopeptide congeners. 
In antibacterial assays run against a wild-type (ATCC 6538P) and  
methicillin resistant (USA300) Staphylococcus aureus, the sulfated 
teicoplanin aglycone analogs show similar activity to vancomycin and 
teicoplanin (Sieradzki, Leski et al. 2003; Diep, Gill et al. 2006).  The general 
trend observed within this family of metabolites is that each successive 
sulfate addition increases the MIC slightly (Table 2). While sulfates have 
rarely been seen in naturally occurring glycopeptide antibiotics, a related 
negatively charged substituent, a phosphono group appears on the DPG at 
position seven in telavancin (27), a second-generation semisynthetic 
glycopeptide antibiotic (Figure 12) (Higgins, Chang et al. 2005). The 
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phosphono group, which likely mimics the naturally occurring sulfate 
functionality that has been seen in a small number of known glycopeptide 
congeners, is reported to markedly improve the ADME (absorption, 
distribution, metabolism, and excretion) characteristics of telavancin. 
Table 2: MIC (µg/mL) for Compounds 20-26, 28-36, and the Teicoplanin Aglycone 
Compound S. aureus E. faecalis 
 ATCC 6538P USA300 ATCC 47077 EF18 
20 2 2 16 >16 
21 1 1 16 >16 
22 3 4 >16 >16 
23 3 2 >16 >16 
24 8 8 >16 >16 
25 8 8 >16 >16 
26 16 8 >16 >16 
28 2 2 16 >16 
29 1 1 8 >16 
30 3 8 >16 >16 
31 3 8 >16 >16 
32 2 2 8 >16 
33 2 4 16 >16 
34 16 16 >16 >16 
35 8 16 16 >16 
36 2 4 16 >16 
teicoplanin aglycone 1 1 8 >16 
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Figure 12: Telavancin (27) and A47934 (28) 
 
An additional discovery, which came out of the glycopeptide pathway 
sequencing and annotation was the observation of the high level of 
conservation in the ordering of genes in the eDNA-derived pathways (Figure 
9). There even appeared to be conserved regions, where, for example, genes 
conferring self-resistance are clustered together, in the same relative location 
from pathway to pathway. This held true for not only resistance elements, 
but also for the large NRPS systems, the genes responsible for the 
biosynthesis of non-canonical amino acids, as well as the genes encoding the 
“tailoring enzymes,” the proteins responsible for the majority of the 
glycopeptide chemical diversity. These tailoring enzymes convert the linear 
heptapeptide precursor peptide to the fully cross-linked, modified active 
product. Therefore, the sequencing data not only provided information about 
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the types and numbers of transformations carried out in each pathway, but 
also provided insight into the conservation of these pathways, which proved 
ultimately very useful for the production of novel glycopeptide congeners. 
With such an arrangement, it is possible to capture large portions of 
glycopeptide tailoring enzyme systems on single eDNA derived cosmid clones. 
The genes found on these clones would be useful for generating glycopeptides 
with novel functionalization patterns.  
Due to the dearth of naturally occurring anionic glycopeptides 
characterized to date, and the promising improvement in ADME profile in 
telavancin by the addition of a group which somewhat mimics the sulfate 
seen in naturally derived anionic glycopeptides, the possibility of using the 
genes found on the six eDNA derived tailoring enzyme-rich clones to generate 
additional sulfonated glycopeptides using both in vivo and in vitro 
derivatization strategies was explored. For the in vivo derivatization studies, 
each tailoring enzyme-rich clone was initially retrofitted with the genetic 
elements necessary for transfer and integration into Streptomyces and then 
transferred by conjugation into Streptomyces toyocaensis (Matsushima and 
Baltz 1996). S. toyocaensis is the natural producer of the monosulfated 
glycopeptide congener A47934 (28) (Figure 12) (Boeck and Mertz 1986).  With 
the exception of the sulfate found on the N-terminal HPG, A47934 is devoid 
of tailoring enzyme-derived functionality.  Thus, A47934 provides numerous 
sites where new functionality could be added by eDNA derived tailoring 
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enzyme genes introduced into S. toyocaensis.  While it is unlikely that all of 
the tailoring enzymes from any one clone would be functionally expressed 
using this strategy, the fact that each clone contains genes for multiple 
potential modification enzymes significantly increases the likelihood of new 
functionality being introduced onto A47934. 
Cultures of both wild type S. toyocaensis as well as S. toyocaensis 
transformed with each of the six retrofitted eDNA cosmids were grown in 
Streptomyces antibiotic medium for 7 days and then crude glycopeptide 
extracts were generated from the resulting culture broths (Lamb, Patel et al. 
2006).  Reversed-phase HPLC analysis of the crude extracts indicated that 
five out the six S. toyocaensis transformants produced new A47934 
derivatives.  Each new compound was HPLC-purified and then analyzed by 
HRMS.  Based on the molecular formulas predicted by HRMS, the 
introduction of either clone UTA15 (VEG pathway) or clone AZ205 leads to 
the addition of a new methyl substituent onto A47934, the introduction of 
clone UTD30 (TEG pathway) leads to the addition of a second sulfate onto 
A47934 and the introduction of either clone CA191 (CA37 pathway) or clone 
CA1627 (CA915 pathway) leads to the addition of a sugar onto A47934 
(Figure 11).  The position of each new functional group was determined by 
comparing 1D and 2D NMR spectra obtained from A47934 with those 
obtained from each derivative (Figures 33-48 in the Appendix). 
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Compound 29, the C-terminal methyl ester of A47934, is produced by 
S. toyocaensis transformed with clone UTA15.  The new oxygen substituted 
methyl (53.21 ppm in 1H-13C HMQC spectra) is visible as a deshielded singlet 
(3.85 ppm) in the 1H spectra and an 1H-13C HMBC correlation from this new 
methyl to the C-terminal carbonyl carbon at 172.32 ppm, allowed us to 
position the methyl at the C-terminus of the heptapeptide (Table 17-18 in the 
Appendix and Figures 36-38 in the Appendix).  Clone UTA15 contains three 
predicted methyltransferases (Table 7 in the Appendix), two of which are 
predicted to encode N-methyltransferases.  The methyltransferase encode by 
the third methyltransferase gene found on this clone is therefore likely 
responsible for the addition of the methyl group to A47934. 
The position of the second sulfate found on the disulfonated derivative 
of A47934 (compound 30) that is produced by S. toyocaensis transformed with 
clone UTD30, was elucidated based on changes in 13C chemical shifts 
observed for the HPG at position 4 in the heptapeptide (Figure 11, Tables 17-
18 in the Appendix and Figures 39-41 in the Appendix).  In compound 29, the 
chemical shift for carbon 4d shifts up field by 4.70 ppm and the chemical shift 
for the carbons ortho to this carbon (4c and 4e) shift downfield by 5.12 and 
4.76 ppm, compared to the chemical shifts for these same carbons in A47934.  
This pattern of chemical shift changes is predicted to arise from the 
sulfonation of an aromatic hydroxyl and mimics the changes we observed 
when the TEG14 sulfotransferase was used to sulfonate the teicoplanin 
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aglycone in vitro (Pretsch 2009). The teg14 gene is found on clone UTD30 and 
TEG14 is likely responsible for this modification in vivo as well. 
Cultures of S. toyocaensis transformed with either cosmid CA191 or 
cosmid CA1627 produce spectroscopically identical glycosylated derivatives of 
A47934 (31) (Figure 11).  Based on the new chemical shifts and observed 
coupling constants seen in 1D and 2D NMR experiments this new sugar 
substituent was determined to be a β-linked D-glucose (Tables 17-19 in the 
Appendix and Figures 41-45 in the Appendix) (Pretsch 2009). As is the case 
with the disulfonated derivative of A47934 described above, changes in 13C 
chemical shifts for the carbons found in the HPG at position 4 in the 
heptapeptide allowed us to place the glucosyl-group on this amino acid.  Both 
cosmid CA191 and cosmid CA1627 contain multiple genes encoding 
glycosyltransferases that could be responsible for appending the glucose 
moiety onto A47934 (Tables 9 and 11 in the Appendix, respectively). 
Compound 32, the N-terminal methyl amine of A47934, is produced by 
S. toyocaensis transformed with clone AZ205.  As seen with compound 29, the 
1H and 1H-13C HMQC NMR spectra from compound 32 indicate the presence 
of a new heteroatom-substituted methyl substituent (1H 2.48 ppm, 13C 31.34 
ppm) (Figure 11, Tables 17-18 in the Appendix, and Figures 46-48 in the 
Appendix).  In this case, however, the chemical shifts suggest that the methyl 
is bound to a nitrogen atom instead of an oxygen atom.  An 1H-13C HMBC 
correlation from the new methyl to the alpha carbon (64.25 ppm) of the HPG 
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at position one in the heptapeptide confirmed the N-terminal methylation in 
compound 32.  ORF10 in clone AZ205 is predicted to encode an N-methyl 
transferase that is likely responsible for the addition of the methyl to the N-
terminus of A47934 (Table 12 in the Appendix). 
Many of the tailoring enzymes encoded on eDNA clones will not be 
expressed in a particular heterologous system and the activity of others is 
undoubtedly thwarted either by incompatibly with the available substrate or 
by the occupation or absence of the site to be functionalized.  In A47934, for 
example, the hydroxyl on HPG1 is blocked by a sulfate and TYR2 is missing 
the beta carbon oxidation that is often seen in glycopeptides.  Even with 
these limitations five out of six eDNA-derived tailoring enzyme-rich clones 
resulted in the production of new A47934 derivatives.  The addition of clones 
in a combinatorial fashion or the cloning of individual eDNA derived tailoring 
enzymes under the control of model promoters would likely provide access to 
even more highly functionalized derivatives, as would the introduction of 
tailoring enzyme rich cosmid clones to an array of glycopeptide producers. 
By coupling the in vivo approach used to generate compounds 29 - 32 
with the in vitro approach used to generate compounds 20 - 26, we were able 
to produce an additional set of sulfated A47934 analogs (Figure 11) (Banik 
and Brady 2008). In the presence of the co-substrate 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) and the teicoplanin aglycone, recombinant AZ205 
sulfotransferase expressed as a HIS-tagged protein in E. coli was found to 
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produce a monosulfated teicoplanin aglycone that is spectroscopically 
identical to compound 21, the sulfated product generated by Teg13.  Both 
sulfotransferases from clone AZ205 and TEG13 therefore specifically sulfate 
the beta carbon hydroxyl on the beta-hydroxytyrosine (BHT) found at 
position six in glycopeptides.  Sulfonation reactions using recombinant AR205 
sulfotransferase were subsequently carried out on A47934 as well as on each 
of the A47934 derivatives that were generated in vivo.  For compounds 28, 
30, 31, and 32, we observed complete conversion of each metabolite to a new 
polysulfated derivative (33, 34, 35, and 36) after 16 h.  In each case HRMS 
confirmed that one additional sulfate had been added to the glycopeptide 
starting material.  As expected from the addition of a sulfate, each beta 
carbon proton at position six is deshielded by ~0.4 ppm compared to the 
chemical shift for this same proton in the starting material (Figure 49 in the 
Appendix).  No reaction was observed when compound 29 was used as a 
substrate.  Methylation of the C-terminal carboxylic acid must disrupt a key 
interaction that is required for catalysis or substrate recognition by the 
AR205 sulfotransferase. 
In total, fifteen new sulfated glycopeptides have been generated using 
the enzymes found on tailoring enzyme-rich clones recovered from the UT, 
CA and AZ eDNA mega-libraries (Figure 11).  This represents a significant 
addition to the number of sulfonated glycopeptides that have been 
characterized thus far.   Minimum inhibitory concentrations (MIC) for each 
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compound were determined using glycopeptide sensitive (Staphylococcus 
aureus ATCC 6538P, Enterococcus faecalis ATCC 47077, methicillin resistant 
(Staphylococcus aureus USA300 (Diep, Gill et al. 2006)) and glycopeptide 
VanA-type resistant (Enterococcus faecalis EF18 (Mato, de Lencastre et al. 
1996)) bacteria (Table 2).  As has been seen with other glycopeptide 
congeners, the more highly functionalized derivatives tend to show higher 
MICs.  While highly functionalized glycopeptide congeners often show 
increased in vitro MICs, they have proved useful as therapeutics because 
some exhibit better pharmacological properties in vivo.  The systematic 
introduction of tailoring enzyme-rich clones to easily cultured glycopeptide 
producers should prove to be a simple yet effective strategy for generating 
collections of glycopeptides with new functionalization patterns that can be 
examined for improved biological activities.  
 
2.4 Discussion and Future Directions 
The production of novel glycopeptides serves to increase the chemical 
diversity of this important class of molecules. The work contained in this 
chapter has more than doubled the number of sequenced glycopeptide 
biosynthetic gene clusters. The ability to combine both in vivo and in vitro 
approaches to molecule production and to identify novel glycopeptide clusters 
expands an already powerful molecular toolbox. It also appears likely that 
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the culture-independent methods used to identify the new glycopeptide 
pathways described herein may yield drastically different new molecules. 
Prior to this work, only two of the over 150 glycopeptides reported were 
sulfonated. However, two of the six pathways discovered as part of this work 
contain confirmed sulfotransferases, suggesting that perhaps sulfonation 
may be a more common functionalization in glycopeptide biosynthesis than 
previously estimated. It also appears very likely that, even in such an 
intensively researched group of small molecules, there is considerable 
chemical diversity remaining undiscovered.  
The discovery of new glycopeptide pathways and the production of 
novel glycopeptide congeners, while an important proof of principle, would be 
monumentally more impactful and long-term beneficial if the molecules 
produced possessed novel characteristics. One hurdle to the examination of 
the glycopeptides produced herein is that, for those produced in vitro, the cost 
of production is a glaring impediment to the increase of scale to a level 
required for extensive assays. To that end, the transition of enzymatic 
processes carried out in vitro to in vivo reactions will significantly decrease 
the overall cost of production. The ability to produce a novel congener entirely 
in vivo will lead to the production of compound in quantities sufficient to 
truly investigate the therapeutic properties, and transition the field of eDNA-
derived glycopeptides from novelty to limitless potential. 
 
53 
 
2.5 Materials and Methods 
2.5.1 PCR screening of eDNA for oxyC sequences 
Crude eDNA samples were prepared from soil samples collected in 
Pennsylvania (2 samples), New Jersey, Massachusetts (2 samples), Utah, 
Oregon, North Carolina, Tanzania (2 samples), and Costa Rica using 
standard eDNA isolation methodology (Brady 2007). In brief: A one to one 
mixture (w/v) of soil and lysis buffer (100 mM Tris-HCl, 100 mM Na EDTA, 
1.5 M NaCl, 1% (w/v) CTAB, 2% (w/v) SDS, pH 8.0) was heated for 2h at 
70°C, and then, the soil was removed by centrifugation (4,000 x g, 30 min).  
Crude environmental DNA was isopropanol precipitated from the 
supernatant with the addition of 0.6 volumes of isopropanol, collected by 
centrifugation (4,000 x g, 30 min), washed with 70% ethanol, and then 
resuspended in TE (10 mM Tris, 1 mM EDTA, pH 8.0).  The remaining soil 
contamination present in the crude extract was removed by large-scale gel 
purification on a 1% agarose gel (16h at 20V), and purified high molecular 
weight eDNA was electroeluted from the gel.  PCR ready eDNA was prepared 
from the gel purified eDNA using the QIAamp DNA Stool Mini Kit (Qiagen).  
OxyC sequences were amplified from these eDNA samples using the following 
nested PCR primers: 1st round forward: 
ATGCTSACSCCSGAGTTCACSGTVCGG, 1st round reverse: 
GCAGTRRTGGAYGCCGTGCCCGAA, 2nd round forward 
CTGTGYGARCTGCTCGGSRTCC, 2nd round reverse 
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CGACRCCRCCSAGGAKCAGC. 100 ng of eDNA was used as a template in 
all first round amplification reactions (cycling parameters: 30 rounds of PCR, 
denatured 95°C for 30 sec, 68°C for 30 sec, 72°C for 90 sec, 25 µL reaction 
conditions: 2.5 µL Thermo Pol Buffer (New England Biolabs), 1.25 µL DMSO, 
0.625 µL of each 100mM oligonucleotide primer, 0.5 µL 10 mM dNTPs mix, 1 
unit of Taq DNA Polymerase and water as needed).  In second round 
amplification reactions 1 µL of the first round PCR reaction was used as a 
template (cycling parameters: 30 rounds of 95°C for 30 sec, 65°C for 30 s, and 
72°C for 30 s, reaction conditions were identical to those used in the first 
round amplification reactions).  Amplicons of the correct predicted size (245 
bp) were gel purified and topo cloned into TOPO 2.1 (Invitrogen).  Eight to 
ten unique clones obtained from each soil sample were sequenced. 
2.5.2 Library construction and screening 
Blunt ended (End-It Kit, Epicentre) eDNA was ligated into either 
pWEB or pWEB-TNC, packaged into lambda phage and transfected into E. 
coli EC100 (Epicentre).  Three libraries, each containing over 2,000 unique 
4,000-5,000 membered libraries were constructed from the transfected E. coli.  
For each unique library, a matching DNA miniprep (Qiagen) and glycerol 
stock set was archived. DNA from the individual 4,000-5,000 membered 
library pools was arrayed into 8X8 grids.  Aliquots of DNA from each pool in 
a grid were then combined into unique sublibraries.  DNA from each 
sublibrary pool was screened by PCR with two different sets of oxyC specific 
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degenerate primers: PS1FWD: 5’-ATGCTSACSCCSGAGTTCACSGTVCGG-3’ 
and PS1REV: 5’-CGAGTRRTGGAYGCCGTGCCCGAA-3’; PS2FWD: 5’-
CCGCAATTCASCMARKMGAARTCSG-3’ and PS2REV: 5’-
TGCCKGGCRAKGAGGTTGTC-3’. PS1 was designed based on the oxyC gene 
sequences found in five cultured glycopeptide producers: (A. orientalis which 
produces chloroeremomycin, A. balhimyceticus which produces balhimycin, S. 
toycaensis which produces A47934, Nonomuraea sp. ATCC 39727 which 
produces A40926, and A. teichomyceticus which produces teicoplanin).  PS2 
was designed to encompass the five oxyC sequences used in the design of PS1, 
as well as the two oxyC sequences previously cloned from eDNA. Each 25 µL 
PCR reaction contained 0.5 µL of cosmid DNA, 2.5 µL of ThermoPol Buffer 
(New England Biolabs), 1.25 µL of DMSO, 0.625 µL of each 100mM 
oligonucleotide primer, 0.5 µL of 10 mM dNTPs mix and 1 unit of Taq DNA 
Polymerase.  For the PS1 primer set, the cycling parameters were as follows: 
7 touch down cycles of 95°C for 30 s, 70-62°C (-1°C/cycle) for 30 s and 72°C for 
90 s followed by 20 cycles of 95°C for 30 s, 62°C for 30 s, 72°C for 90 s.  For 
the PS2 primer set the following cycling parameters were used: 30 cycles of 
95°C for 30 s, 62°C for 30 s, 72°C for 30 s.  PCR amplicons of the correct 
predicted size (700-800 bp for PS1 and 380-410BP for the PS2) were gel 
purified, A/T cloned into PCR2.1 (Invitrogen) and sequenced.  DNA from the 
individual pools that were used to create each large sublibrary that yielded 
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an oxyC sequence of interest was then screened using the same set of PCR 
primers.   
2.5.3 Clone recovery and sequencing 
Once an individual sublibrary pool containing that sequence was 
identified, the cosmid of interest was recovered from the corresponding 
glycerol stock using successive rounds of serial dilution and PCR screening.  
Recovered cosmid clones were end-sequenced using vector specific primers: 
T7 Promoter and M13 Universal Fwd -40.  End-sequencing data was used to 
design new sets of PCR primers that could be used to recover clones 
containing overlapping DNA sequences.  This PCR screening process was 
repeated iteratively as needed for each gene cluster. 
All cosmid clones were 454 sequenced (Roche) by the Memorial Sloan 
Kettering Cancer Center Genomics Core Laboratory.  Raw reads were 
processed with Newbler (Roche) and Velvet ((Zerbino and Birney 2008)).  
Sequence manipulation and gene identification were carried out using 
MacVector and BLASTX, respectively. The specificity of each NRPS 
adenylation domain was determined using NRPS-PKS web-based analysis 
((Ansari, Yadav et al. 2004)). 
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2.3.4 Cloning, Expression, and Purification of TEG11, 12, and 13 
Sulfotransferase Genes 
teg11, teg12, and teg13 were amplified (30 cycles of 95°C for 30s, 60°C for 30s 
(65°C for AZ205 Sulf) and 72°C for 90s, FailSafe system from Epicentre) from 
clone D30 for teg12-14 and AZ205 for AZ205Sulf using the following primers: 
TEG12FWD(BclI): GCGCTGATCAATGAACGGAATTCGATGG, 
TEG12REV(HindIII): GCGCAAGCTTTCCTTAACCGGCATACCCGTA, 
TEG13FWD(BclI): GCGCTGATCAATGAACGGCATTCGATGGATC, 
TEG13REV(HindIII): GCGCAAGCTTATCTCTCCTCCCTCAGCCGGC, 
TEG14FWD(BclI): GCGCTGATCAATGAACGGTATTCGATGGATC, 
TEG14REV(HindIII): GCGCAAGCTTACAATCCGCCCGTTAGCCGGC, 
AZ205SulfFWD(BamHI) GCGCGGATCCATGAACGGAATCCGATGG and 
AZ205SulfREV(HindIII) GCGCAAGCTTTCCCTAATCAGCGTACCCGTA. 
The restriction sites added for cloning purposes are shown in bold.  
Amplicons were doubly digested with either BclI/HindIII or BamHI/HindIII, 
ligated into the BamHI/HindIII digested pET28a, and then transformed into 
E. coli BL21 (DE3). 
Fusion protein purification and sulfation reaction protocols were 
modified from published procedures used for StaL (Lamb, Patel et al. 2006).  
Overnight growths were used to inoculate (1:1000 dilution) 1 L cultures of 
LB, which were grown at 37°C until the OD600 reached 0.6.  The temperature 
was then reduced to 20°C, and after 1h, the cultures were induced with IPTG 
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(0.5 mM).  After 14-16h at 20°C, the cultures were harvested by 
centrifugation (3,200 x g for 30 minutes).  The cell pellet was resuspended in 
40 mL of lysis buffer (50 mM HEPES, pH 7.5, 0.5 M NaCl, 5% (v/v) glycerol, 
20 mM imidazole, pH 8, 10 mM β-mercaptoethanol, and 0.5 % (v/v) Triton X-
100), and the cells were lysed by sonication.  Crude cell lysates were 
centrifuged at 25,000 x g for 30 minutes, and the supernatants were then 
incubated for 15 min (24°C) with 1 mL of Ni-NTA resin.  After 15 min, this 
slurry was loaded onto a column, washed with 40 mL of lysis buffer, followed 
by 40 mL of wash buffer (50 mM HEPES, pH 7.5, 0.5 M NaCl, 5% (v/v) 
glycerol, 20 mM imidazole, pH 8, and 10 mM β-mercaptoethanol), and then 
the protein was eluted from the resin with 15 mL of elution buffer (50 mM 
HEPES, pH 7.5, 0.5 M NaCl, 5% (v/v) glycerol, 125 mM imidazole, pH 8, and 
10 mM β-mercaptoethanol).  The protein concentration was determined with 
the Bradford assay (yields: 74 mg/L TEG12, 31 mg/L TEG13, 88 mg/L TEG14, 
and 65 mg/L AZ205Sulf) and these samples were used in sulfation reactions 
without further purification.  Two mililiter sulfonation reactions containing 
1mg of each sulfotransferse, 1 mg teicoplanin aglycone and 0.5 mg 3'-
phosphoadenosine 5'-phosphosulfate (PAPS) were setup in reaction buffer 
(250 mM HEPES, pH 7.5, 0.1 mM DTT) and incubated overnight at 30°C (For 
in vitro reactions with compounds isolated from culture extracts (compounds 
28, 30, 31, and 32), reactions were scaled to 6 mL).   Excess sulfotransferase 
was added to overcome the known inhibition of PAPS dependent 
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sulfotransferases by the sulfotransferase byproduct 3’-phosphoadenosine 5’ 
phosphate (PAP) (Chapman, Best et al. 2004).  The reactions were then 
placed in a boiling water bath for 10 minutes, placed on ice for 10 minutes, 
and centrifuged (21,000 x g at 4°C) for 10 minutes.  The supernatant (and if 
necessary a water wash of the pellet) was evaporated to dryness and 
resuspended in 400 µL of a 50:50 DMSO:H2O (1200 µL for 6 mL reactions). 
The analytical HPLC conditions were as follows: (C18 (4.6 x 150 mm), 20 mM 
ammonium acetate:acetonitrile, 95:5 to 70:30 over 20 min, 1.5 mL/min).  
Preparative HPLC was carried out using the same gradient conditions on a 
10 x 150 mm column at a flow rate of 7 mL/min. 
2.3.5 Cosmid retrofitting and conjugation into S. toyocaensis  
Cosmids containing glycopeptide tailoring enzymes were each 
retrofitted to contain the genetic elements required for conjugation, 
integration and selection in Streptomyces.  Each cosmid was initially digested 
with PsiI (New England Biolabs) and then ligated to the 6.7 kb DraI 
fragment from pOJ436 ((Matsushima, Broughton et al. 1994)).  This DraI 
fragment contains the φC31 integration machinery, the RK2 oriT and the 
aac(3)IV apramycin resistance gene.  Upon transformation into E. coli, 
retrofitted cosmids could be easily identified by selecting with both ampicillin 
and apramycin.  Correctly retrofitted cosmids were transformed into E. coli 
S17.1 and conjugated into Streptomyces toyocaensis NRRL 15009 using 
previously described methods, with a few minor modifications ((Matsushima 
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and Baltz 1996)).  For each conjugation, a 50 mL culture of E. coli S17.1 
transformed with an appropriately retrofitted cosmid clone was grown to 
mid-logarithmic phase (LB with 50 µg/mL apramycin and 10 µg/mL 
trimethoprim).  Cells were then pelleted by centrifugation (3500 x g, 30 min) 
and the resulting cell pellet was washed twice with 50 mL of antibiotic free 
LB.  Washed E. coli were resuspended in 1 mL SOC (per liter: 20 gm Bacto 
Tryptone 5 gm Bacto Yeast Extract 10 mM NaCl, 2.5 mM Kcl, 10 mM MgCl2 
10 mM MgSO4 20 mM glucose).  20 µL of a heat treated (50°C for 10 min) 
spore slurry (OD450=40-80) was mixed with 50 µL of washed E. coli and this 
cell suspension was then plated onto R2 agar.  After 16 hours at 30°C, the 
plates were flooded with 1 mL of sterile water containing 0.5 mg of 
apramycin and 0.5 mg of nalidixic acid and then returned to the incubator 
until exconjugants appeared (3-4 days).  Exconjugants were restruck on 
modified Bennett’s agar containing 25 µg/mL apramycin and 25 µg/mL 
nalidixic acid. 
2.3.6 Glycopeptide congener production 
S. toyocaensis harboring eDNA-derived glycopeptide tailoring enzymes 
was initially grown on modified Bennett’s agar for 3 days at 30°C.  Single 
colonies were inoculated into 50 mL of Streptomyces Vegetative Medium 
(SVM) and incubated at 30°C for 3 days (200 rpm orbital shaking)(Lamb, 
Patel et al. 2006).  50 mL of Streptomyces antibiotic medium containing 1 g/L 
yeast extract (SAM) was inoculated with a 1:1000 dilution of the 3-days-old 
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starter culture (Lamb, Patel et al. 2006). After 7 days (30°C, 200 rpm orbital 
shaking) the cell mass was collected by centrifugation (3500 x g, 10 min).  
The wet weight of the pellet was determined and the pellet was resuspended 
(vortex, 30s) in 0.75 mL of 2.5% (v/v) NH4OH  per gram of wet cell pellet.  
This basic cell suspension (final pH >11) was centrifuged (3500 x g, 10 min) 
and the supernatant collected.  The pH of the supernatant was adjusted to 
7.5 with 1 M HCl, and analyzed directly by HPLC [C18 (4.6 µm X 150 mm), 20 
mM ammonium acetate:CH3CN, from 95:5 to 70:30 over 20 min, 1.5 mL/min 
or C18 (10 µm X 150 mm), 20 mM ammonium acetate:CH3CN, from 95:5 to 
70:30 over 20 min, 7 mL/min]. 
2.3.7 Glycopeptide congener analysis 
Hi-Res ESI-MS experiments were carried out either on a Thermo-
Fisher LTQ-Obritrap mass spectrometer interfaced with a Dionex U3000 
capillary/nano-HPLC system, or by direct injection onto a Waters LCT 
Premier XE mass spectrometer. NMR data was collected for all samples in a 
3:1 mixture of D2O:CD3CN on a Bruker 600 MHz spectrometer and was 
processed using the MestreNova Software Package (MestreLab Research). 
2.3.8 MIC determination 
Stationary phase cultures of Staphylococcus aureus strains and 
Enterococcus faecalis strains, grown in tryptic soy broth and brain heart 
infusion broth, respectively, were diluted 1:106 prior to addition of 
compounds.  Individual wells in 96 well microtiter plates were filled with 100 
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µL of diluted culture.  A stock solution of an individual compound dissolved in 
dimethylsulfoxide was diluted 1:100 into culture media and then 100 µL of 
this solution was added to the first well of a row in the filled microtiter plate.  
This well was then serially diluted 1:2 across the plate.  Microtiter plates 
were incubated at 37°C with 100 rpm orbital shaking for 18 hours.  MIC 
values are reported as the lowest concentration at which no bacterial growth 
was observed. 
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CHAPTER 3 
3 Structural and Biochemical Analysis of eDNA-
derived Glycopeptide Sulfotransferases 
3.1 Chapter Summary 
 Prior to the work contained in chapter 2, there were only two known 
sulfonated glycopeptides (Boeck and Mertz 1986; Holdom 1988). The 
discovery of two new glycopeptide biosynthetic gene clusters containing 
glycopeptide-modifying sulfotransferases and the production of semi-
synthetic glycopeptides displaying anionic modifications led to an increased 
desire to gain a broader understanding of the structural and catalytic 
properties of glycopeptide sulfotransferases. To that end, this chapter 
describes the structural and biochemical analysis of one of these 
sulfotransferases. In collaboration with Dr. Matthew J. Bick and Dr. Seth A. 
Darst of the Darst Laboratory at the Rockefeller University, four separate X-
ray crystal structures have been solved, three of TEG12 and one of TEG14 
(Bick, Banik et al. 2010; Bick, Banik et al. 2010). The three TEG12 structures 
are an apo-structure, a binary structure containing teicoplanin aglycone 
bound to TEG 12, and a ternary structure, containing both 3’-
phosphoadenosine-5’phosphate (PAP) and the teicoplanin aglycone bound to 
TEG12. The TEG14 structure is an apo-structure, which has provided 
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structural information, but limited biochemical data, and therefore has 
largely been omitted from this chapter. The discussion in this chapter will 
therefore be focused on the various TEG12 structures. Upon solution of the 
various TEG12 structures, a number of amino acids appeared to be 
fundamentally important in substrate recruitment, substrate specificity, 
and/or catalytic activity. These key residues were mutated and observations 
were made as to the effects on the enzyme catalytic reactivity. Taken 
together, the structural and kinetic data provide a much better 
understanding of these enzymes and have provided general insight into key 
regions of these proteins, which have allowed three sulfotransferases with in 
excess of 80% amino acid identity to sulfonate the same glycopeptide 
substrate at three different sites. Only a brief description of the details of 
crystal structure solution will be given for the purposes of archiving, as this 
work was carried out exclusively by Dr. Matthew J. Bick and Dr. Seth A. 
Darst, and is outside the expertise of this author.   
3.2 Introduction 
 Sulfonation is one of the rarest modifications seen in glycopeptide 
biosynthesis. Prior to the metagenomics efforts described in chapter 2 of this 
thesis, there were only two known sulfonated glycopeptides, the biosynthesis 
of which was characterized for only one, A47934 (28) (Pootoolal, Thomas et 
al. 2002). The sulfotransferase, which acts during the biosynthesis of A47934, 
StaL, has been well studied, with publications detailing both significant 
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structural and biochemical studies (Lamb, Patel et al. 2006; Shi, Lamb et al. 
2007). However, with only one characterized glycopeptide sulfotransferase, it 
was difficult to gain much more than anecdotal, pathway-specific information 
about this enzyme. This dearth of knowledge became even more pressing 
after the generation of a semi-synthetic derivative of vancomycin, telavancin 
(27), which is modified from its natural product precursor by the addition of a 
long hydrophobic acyl chain and a phosphonic acid moiety to amino acid 
seven of the heptapeptide backbone. This phosphonic acid moiety is 
structurally and chemically rather similar to the naturally occurring sulfate 
seen in A47934 (28). The discovery of four novel sulfotransferases through 
the course of the culture-independent glycopeptide pathway discovery efforts 
described in chapter 2 provided an opportunity for a more in-depth 
investigation into these understudied enzymes. One pathway in particular, 
the TEG pathway, contained three novel sulfotransferases, which displayed 
over 80% amino acid identity to each other. These very closely related 
sulfotransferases sulfonated the same predicted substrate, the teicoplanin 
aglycone, at three different sites. It was observed that, for all intents and 
purposes, there were only three regions that varied within the three enzymes. 
It was therefore hypothesized that a structural analysis of these enzymes, 
coupled with biochemical data, would provide insight into this potentially 
very useful class of proteins. 
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3.3 Results 
3.3.1 TEG12 Structural Overview 
 A ClustalW alignment of the three sulfotransferases found in the TEG 
pathway (TEG12-14) displays the high level of amino acid identity among the 
three enzymes, with three main regions of divergence (Figure 13). These 
three regions, termed variable loops 1-3 (V1,V2, and V3) correspond in 
TEG12 to Ile37-Thr43, Gly127-137, and Thr204-Asp250, respectively. As all 
three TEG sulfotransferases can use the teicoplanin aglycone as a substrate, 
this small molecule was used, along with the cofactor byproduct 3’-
phosphoadenosine-5’phosphate (PAP), in various combinations for co-
crystallization experiments. Vmax and Km were calculated for TEG12 with 
the teicoplanin aglyonce as substrate. These values were found to be 215.3 +/- 
25.2 nmol/min-mg and 559.6 +/- 1.1 µM, respectively.  
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Figure 13: ClustalW alignment of glycopeptide sulfotransferases.  
Highly variable sequences (V1-V3) and the flexible part of the GHL helix appear in colored 
boxes that match the coloration seen in panels B and C of Figure 13. Results from alanine 
exchange mutagenesis experiments are color-coded by percent activity. Results for catalytic 
and PAPS-associated residues are shown in solid and dashed boxes, respectively. All other 
mutated residues are thought to interact with the glycopeptides. The H67A mutant was 
insoluble, and therefore, H67Q data are reported. 
 
Multiple crystal structures of TEG12 were solved, all as homo-dimers: 
an apo-structure solved to 2.91 Å, a binary structure of TEG12 complexed 
with the teicoplanin aglycone, solved to 2.27 Å, and a ternary structure of 
TEG12 containing in both monomers of the dimer a molecule of PAP, and in 
one of the monomers two molecules of the teicoplanin aglycone, solved to 2.05 
Å (Figure 14). All protein used for crystallization was N-terminally His6-
tagged and purified by affinity chromatography on Ni-NTA resin. There was 
no additional purification, nor was there any additional processing to remove 
the 34 vector-derived amino acids, which were later observed to play a 
possible role in crystal packing in the TEG12 structures. The TEG12 crystal 
structures described herein are the first examples of a glycopeptide 
sulfotransferase with substrate bound. The previous crystal structure of 
StaL, the sulfotransferase from the A47934 pathway, described a modeling of 
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the substrate docked with the enzyme, as their various structures contained 
no electron density for the glycopeptide (Shi, Lamb et al. 2007). 
 
Figure 14: TEG12 crystal structures. 
A): TEG12-apo is colored using a rainbow scheme, from blue (N-terminus) to red (C-
terminus). Regions of disorder are connected by gray dots, with the number of disordered 
residues indicated. The flexible GHL helix is colored orange. Side chains for the proposed 
active site residues His67 and Ser9 are also shown. B): TEG12-ternary complex containing 
PAP and the teicoplanin aglycone. The protein is colored gray to accentuate regions of the 
structure that differ from TEG12-apo. Specifically, these regions are variable loops V1-V3, 
colored blue, red, and green, respectively. Also shown are a molecule of PAP in the active 
site, a molecule of teicoplanin aglycone that interacts with the V3 loop (sky blue), and an 
additional molecule of teicoplanin aglycone involved in crystal packing interactions (hot 
pink). C): TEG12-binary structure in a complex with teicoplanin aglycone in the active site 
cavity. Again, the protein is colored gray, with V1-V3 colored as in the ternary structure. 
TEG12 sulfates the hydroxyl of residue 3 of the teicoplanin aglycone, which has been denoted 
with a red arrow. Omitted from the binary structure is a second molecule of teicoplanin 
aglycone bound to the outside of the protein on the opposite side of the GHL helix. 
 
3.3.2 Co-factor-binding Residues 
 
TEG12, like many other PAPS-dependent (3’-phosphoadenosine-5’-
phosphosulfate) sulfotransferases utilize conserved structural motifs to bind 
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this sulfate donating co-factor. A loop in TEG12 comprised of Pro11-Thr16 
represents one of these common motifs, known as the phosphosulfate-binding 
(PSB) loop, due to its coordination of the 5’-phosphosulfate. In the ternary 
structure, Lys12 and Thr16 form hydrogen-bonding contacts with the 5’-
phosphate of PAP and Trp17, which sits just outside the PSB loop, forms a 
parallel stack with the adenine base of PAP (Figure 15). Another conserved 
structural motif, the phosphate-binding loop (Campbell, Singh et al.), is 
comprised of Val89-Ser99, with Ser98 observed to form a hydrogen-bond with 
the 3’-phosphate of PAP in the ternary structure (Campbell, Singh et al.).  
 
Figure 15: PAP bound in theTeg12-ternary complex. 
Leu205 and Met208 from the GHL helix and Phe243 and Val244 fromthe V3 loop make 
significant van der Waals contacts with PAP. 
 
The hydrogen bonds formed between Thr16 and the 5’-phosphate 
mimic hydrogen bonds seen in the StaL crystal structure, although in StaL, 
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there is a histidine at position 16. Nonetheless, the hydrogen bonds, which 
appeared to be important in coordinating PAPS in the StaL structure, are 
present in the TEG12 structure as well. To determine whether these 
hypothesized PAPS coordinating hydrogen bonds were important for catalytic 
activity, alanine replacement mutants were constructed, using a previously 
reported protocol and PCR primers listed (Table 3) and activity experiments 
were carried out (Sarkar 1990). T16A was unable to catalyze the sulfonation 
reaction, as was K12A, confirming the necessity of both residues.  Alanine 
replacement mutants of three other residues implicated in coordinating 
PAPS, Trp17, Lys65, and Ser98, were constructed as well. W17A did not 
express as soluble protein, confirming its role in protein stability, but leaving 
its necessity for PAPS binding as solely an inferred role. K65A and S98A 
produced enzymes with only partial activity (65% and 27% relative to wild-
type, respectively). Additional alanine replacement mutations were 
constructed for Arg 90 and Tyr167, which are each seen to interact with both 
PAP and the aglycone in the ternary structure. Unfortunately, neither R90A 
nor Y167A expressed as soluble protein, suggesting an additional possible 
structural stability role.  
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Table 3: Oligonucleotide primers used for the generation of site-directed mutants 
in TEG12 
Mutant Primer (5’-3’) 
S9A GTTTCCAGCCTTTGGATACGCTGCGATCCATCGAATTCC 
K12A CCACGTGTTTCCAGCCGCTGGATACGATGC 
T16A CACCTGACCCACGCGTTTCCAGCCTTTGG 
W17A CAACATGCACCTGACCGCCGTGTTTCCAGC 
K65A CATCGGCCTTGAGGTGCGTCGCCACCAGCACCGGTTC 
H67A CACATCGGCCTTGAGGGCCGTCTTCACCAG 
R90A CATATCCCGCGGGTTCGCCACGAGATAGAG 
S98A GGCCATGCGATCGAGGCGAGCAGCATATC 
R101A TATCGAGGCCATGGCCATCGAGCTGAG 
S106A CTACGTCGTCGCGCGCTATCGAGGCCATGCG 
R107A GCTTTTTTCTACGTCGTCGGCCGATATCGAGGC 
D108A GCTTTTTTCTACGTCGGCGCGCGATATCGAGGCC 
Y167A GTGCTGACGATGCGTGCTGAGGACCTGAAGGGC 
K171A CGTTATGAGGACCTGGCGGGCGATCCGGTCGCACGG 
E206A GCTGCCTCCACGCTGGCGCGGATGCGTGAACTG 
R207A GCTGCCTCCACGCTGGAGGCGATGCGTGAACTG 
E210A GAGCGGATGCGTGCACTGGAGAAACGGAG 
E212A CGGATGCGTGAACTGGCGAAACGG 
K213A CGGATGCGTGAACTGGAGGCACGGAGCGAGCAGCAG 
R214A CGGATGCGTGAACTGGAGAAAGCGAGCGAGCAGCAG 
M232A GGTGATGCGAGAATGGCGAAAGGG 
K233A GATGCGAGAATGATGGCAGGGGG 
G234A GCGAGAATGATGAAAGCGGGACC 
G235A AGAATGATGAAAGGGGCACCTGGTG 
P236A ATGATGAAAGGGGGAGCTGGTGG 
G238A AAAGGGGGACCTGGTGCCGCGAGG 
A239R AAAGGGGGACCTGGTGGCCGGAGG 
R240A GGACCTGGTGGCGCGGCGCCCCAG 
P241A CCTGGTGGCGCGAGGGCCCAGTTC 
Q242A GGTGGCGCGAGGCCCGCGTTCGTG 
R248A CAGTTCGTGGGCGAGGGCGCGTACGACCAGTCCCTG 
Q251A GAGGGCAGGTACGACGCGTCCCTGTCCTTCTTG 
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3.3.3 Residues Involved in Catalysis 
 It had been previously hypothesized that PAPS-dependent 
sulfotransferases, like TEG12, utilize conserved histidines, which act as 
general bases to activate the hydroxyl or amino groups in the sulfate 
exchange from PAPS to substrate. Of the three histidines in TEG12, only 
His67 is located near the molecule of PAP in the ternary structure, in fact 
modeling PAPS in for PAP in the ternary structure places the 5’-sulfate 
directly adjacent to His67 (Figure 16). Mutation of His67 to alanine yieled 
insoluble protein, as did the H67E mutant. However, mutation of His67 to 
glutamine yielded a soluble, but fully inactive, enzyme. Both the histidine at 
position 67 and a serine at position 9 are conserved between StaL and 
TEG12. Ser9 is thought to hydrogen bond to the imidazole ring of the 
histidine and aid in catalytic activation. Unfortunately, an alanine 
replacement mutant of Ser9 yielded insoluble protein, so as with Trp17, the 
role played by this amino acid can only be inferred from the crystal structure. 
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Figure 16: Composite of the active site from the Teg12-binary and-ternary 
structures.  
PAPS was modeled into the ternary structure in place of PAP. In this aligned view, PAPS 
and teicoplanin aglycone would not be able to occupy their respective positions 
simultaneously, as there would be strong clashes between the two substrates. Residue 3 of 
the teicoplanin aglycone, the site of sulfation, is more than 16 Å from the sulfate of PAPS 
when the ternary and binary structures are overlapped. A substantial rearrangement of 
teicoplanin aglycone within the active site would have to occur for sulfation to proceed by the 
proposed in-line attack mechanism. The positions of Arg101 in the binary (green) and 
ternary (tan) structures appear to preclude the movement of teicoplanin aglycone toward 
His67. Arg101’s position in the context of the apo structure creates a more open active site, 
where the aglycone could pivot toward His67 more easily. 
 
3.3.4 The Glycopeptide Helix Loop (GHL) 
 There are a few regions, which vary in their level of disorder amongst 
the three TEG12 structures (Figure 14). In the apo-structure, the regions 
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from Gly127-Val137 and from Thr204-Asp250 are almost completely 
disordered. However, in the binary structure, the latter of those two regions, 
which corresponds to a region containing variable loop 3 (V3), becomes 
slightly more ordered. In the ternary structure, this region is almost fully 
ordered. The stabilization in this region is due largely to interactions between 
the protein and the glycopeptide substrate that is bound in these co-crystal 
structures. This region is also the largest region of variability amongst the 
three TEG sulfotransferases (TEG12-TEG14). Due to the protein-substrate 
interactions, the region slightly upstream of V3 and V3 has been collectively 
labeled the glycopeptide helix loop (GHL) (Figure 14). Based on the 
significant number of contacts made between the protein and the substrate, 
as well as the variability in the TEG sulfotransferases in V3, it seemed quite 
likely that the GHL could play a very significant role in this enzyme, perhaps 
in substrate recruitment, and shuttling of substrate to the active site. 
 In the binary structure, the GHL helix and a helix, which extends from 
Ile193-Ser203 form a single helix that runs along the top of the glycopeptide 
substrate, while in the ternary structure, this single contiguous helix is 
kinked at ~90°, which is similar to the orientation adopted by these helices in 
the StaL structure (Figure 14). The position occupied by the GHL and PAP in 
the ternary structure overlaps the position of the teicoplanin aglycone 
substrate in the binary structure, indicating the great degree of movement 
and flexibility found in this region of the protein. The displaced, disordered 
75 
 
loop that contacts PAP in the ternary structure is located behind the bound 
glycopeptide substrate in the binary structure. Other than the movement 
seen in this loop, the binary structure differs little from either the apo- or the 
ternary structures. In addition to the interactions with the GHL, the 
glycopeptide substrate also forms interactions with the PSB and PB loops. 
The PSB loop directly interacts with the C-terminus of the glycopeptide 
substrate, while the PB loop runs underneath the glycopeptide in the binary 
structure.  
 There are two molecules of the teicoplanin aglycone found in one of the 
monomers of the ternary structure, although neither of these molecules was 
located in the active site of the enzyme. There are numerous contacts made 
between one of these molecules and the GHL loop (Figure 17). A number of 
residues within the GHL were mutated to determine the effects of changes 
within this loop would alter the sulfotransferase activity. Glu212, which does 
not directly interact with the glycopeptide in the binary structure, when 
mutated to alanine, displays a vastly reduced level of enzyme activity (26% 
relative to wild type). Additional alanine replacement mutations in the GHL 
led to varied effects on the activity of TEG12. Alanine replacement mutations 
of three residues seen to make hydrogen bonding contacts in the binary 
structure, Glu206, Arg207, and Glu 210 led to complete loss of activity, only 
slight (79% relative to wild type) loss of activity, and negligible (97% relative 
to wild type) change in activity, respectively. Three other GHL residues were 
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mutated to alanine and assessed for relative activity. E212A, K213A, and 
R214A displayed activities relative to wild type of 26, 99, and 67%, 
respectively.  
 
Figure 17: Close-up of the GHL loop aglycone complex from the Teg12-ternary 
structure.  
Side chains for all alanine replacement experiments are shown. Lys233 intercalates into the 
glycopeptide and makes hydrogen bond contacts with residues 1 and 7 of the aglycone. 
 
Another large stretch of the GHL (Met232-Pro236 and Gly238-Gln242) 
interacts directly with the teicoplanin aglycone in the ternary structure. 
Alanine replacement mutations of these residues, which directly interact 
with the aglycone, have been constructed and kinetics data recorded (Table 
4). Not surprisingly, all but the mutation of Gly235 to alanine led to a 
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decrease in enzyme activity. Two additional residues outside the GHL, which 
are not directly observed to make contact with the substrate or cofactor in 
either the binary or ternary structures, but instead are seen to define the 
contour of the active site, Arg248 and Gln251 were also mutated to alanine. 
Interestingly, while Q251A resulted in a marked decrease in enzyme activity, 
R248A resulted in an almost two-fold increase in enzyme activity. It seems 
likely, in the case of R248A, that the removal of the steric bulk of the 
arginine side chain creates a more flexible active site, which is more 
amenable to accommodating the sizable glycopeptide substrate. This 
hypothesis is further supported by the substitution in StaL of a glycine for 
the arginine at position 248, which is conserved in all of the TEG 
sulfotransferases.  
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Table 4: Relative activity of TEG12 mutant sulfotransferases 
    
Catalytic or 
PAP     binding 
Activity 
(%) 
V3 
aglycone 
binding 
Activity 
(%) 
Non-V3 
aglycone 
binding 
 Activity 
(%) 
S9A N/A M232A 74 R101A 29 
K12A 0 K233A 79 S106A 92 
T16A 0 G234A 82 R107A 82 
W17A N/A G235A 100 D108A 82 
K65A 61 P236A 73 Y167A N/A 
H67A N/A G238A 56 K171A 69 
H67E N/A A239R 37 E206A 0 
H67Q 0 R240A 48 R207A 79 
R90A N/A P241A 0 E210A 97 
S98A 27 Q242A 64 E212A 26 
    K213A 99 
    R214A 67 
    R248A 196 
        Q251A 41 
 
3.3.5 Sulfotransferase Intercalation in the Glycopeptide Substrate 
 In both the binary and ternary structures, there are individual amino 
acids (Arg101 in the binary and Lys233 in the ternary structure) that 
actually interacalate into the inner surface of the teicoplanin aglycone 
(Figure 16). All other substrate-protein interactions involve the external 
surface of the glycopeptide. These long, positively charged side chains 
intercalate between amino acids 3 and 5, forming a number of hydrogen 
bonding contacts. Although the binding observed for Arg101 and Lys233 is 
very similar in its nature, the effect of mutation of these residues to alanine 
is drastically different. R101A possesses only a small fraction of the activity 
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of wild-type TEG12 (27%), while K233A is only marginally affected (79% 
relative to wild-type).  
3.3.6 Second Molecule of the Teicoplanin Aglycone in the Ternary 
Structure 
 As earlier mentioned, there is electron density corresponding to two 
molecules of the teicoplanin aglycone in the ternary TEG12 structure. The 
second of these two molecules, which is bound to the enzyme considerably 
farther away from the active site than the other molecule of aglycone, 
appears to simply be forming crystal contacts between adjacent symmetry 
partners. However, there is a region of electron density near this second 
molecule of aglycone, which is most likely hydrogen bonding of vector-derived 
amino acids. The region occupied by this density is the same as that observed 
for the binding of the D-ala-D-ala tail of peptidoglycan, which is the 
traditional target for glycopeptide antibiotics (Nicolaou 1999). Although it is 
quite likely that these interactions are of no biological importance to the 
sulfotransferase, they are nonetheless reminiscent of the true role of the 
glycopeptide cleft. 
3.4 Discussion and Future Directions 
 There are a number of residues that, based on alanine replacement 
mutations, are essential for catalytic conversion of the teicoplanin aglycone to 
sulfo-teicoplanin aglycone by TEG12. TEG12 sulfates the teicoplanin 
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aglycone at the DPG at position 3. The conserved histidine, His67, has been 
confirmed in its role in the sulfonation reaction. All but two of the predicted 
catalytic or substrate binding residues (K65A and S98A) were found to be 
either essential to catalysis or to play an essential structure stabilizing role, 
based on the expression of insoluble protein. All but one of the alanine 
replacement mutants generated for residues in the GHL led to a diminished 
capacity for substrate conversion.  
It is impossible from the current structural and kinetics data to 
determine which of two possible reaction mechanisms take place. It is 
possible that the sulfate group is first covalently attached to the catalytic 
histidine, forming a sulfo-TEG intermediate. Alternatively, the catalytic 
histidine could act as a general base, as is depicted in Figure 17. Both 
strategies have been documented in various prokaryotic and eukaryotic 
sulfotransferases (Chapman, Best et al. 2004). Even in very distantly related 
sulfotransferases such as TEG12 and the human cytosolic sulfotransferase 
SULT1A1, which only display 20% amino acid identity, the catalytic histidine 
is conserved, as is the serine which is predicted to aid in subsrate activation.  
Possible experiments that could lead to the determination of which of the two 
mechanisms is correct include low-energy ionization mass spectrometry to 
attempt to identify the sulfo-TEG intermediate, or kinetic experiments where 
the effect of PAPS concentration on the initial velocity of the enzyme. These 
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and other experiments could lead to the elucidation of which reaction 
mechanism is correct.  
 Although the interactions of the substrate teicoplanin aglycone and the 
protein vary between the binary and ternary structures, the observation of a 
long, positively-charged side chain intercalating into the middle of the 
glycopeptide is common in both structures. Arg101, based on its position in 
both structures, appears to play an important role in the active site 
dynamics. Arg101 appears to block the glycopeptide from entering the active 
site and gaining access to the catalytic histidine (His67). In the ternary 
structure, Arg101 interacts directly with the 3’-phosphate of PAP and does 
not appear to interact with the glycopeptide whatsoever. However, in the apo-
structure, Arg101 adopts a confirmation that would open up the active site to 
accommodate both the glycopeptide substrate and the PAPS cofactor. It 
seems likely then that Arg101 plays an important role in modulating active 
site dynamic changes, which are required for catalysis. 
 The portion of the GHL loop and the loop directly preceding it, as 
mentioned earlier, form a single, contiguous loop in the binary structure, 
while they are two distinct loops, with a 90° kink in between. The distance 
between the ends of the straight, longer loop and the kinked loop is 
approximately 16 Å. This is also the distance between the site of sulfonation 
of the glycopeptide substrate and His67 in the binary structure. The 
flexibility of this loop seems very likely a significant factor in the ability of 
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this protein to act on such a large substrate, much larger than most 
sulfotransferase substrates. The interactions seen in the binary structure 
between the substrate and this loop, based on the diminished enzyme activity 
of alanine replacement mutations, appear to represent a snapshot on the 
path the substrate takes from outside the enzyme to the active site. The 
residues that interact in the GHL with the glycopeptide in the binary 
structure are seen to point in an outward direction in the ternary structure, 
suggesting that their role is more for shuttling the substrate to the active 
site, and that other contacts likely moderate the unique substrate positioning 
in the active site. The conservation of the GHL in the three TEG 
sulfotransferases (and largely in StaL as well) lends further credence to this 
hypothesis.  
The role of substrate positioning is likely played by the V3 residues, 
which would account for the variation in the site of sulfonation in the three 
TEG sulfotransferases. The varied binding of the substrate, and the 
presentation of different faces of the glycopeptide to the catalytic residues in 
the active site are likely responsible for this diversity. One possibility for 
generating variation in these sulfotransferases is to simply exchange the 
GHL regions from one TEG sulfotransferase for another. Exchange of the 
entire GHL region in TEG12 for the GHL region from TEG13 or TEG14 led to 
the expression of soluble protein at quantities similar to wild-type. However, 
in both cases (TEG12 GHL exchanged fro TEG13 GHL and TEG12 GHL 
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exchanged for TEG14 GHL), all catalytic activity was abolished. The enzymes 
neither retained their original activity nor gained new activity. It therefore 
seems likely that each individual V1-V3 collection is required for each specific 
sulfonation reaction. Therefore, the roles played by V1 and V2 cannot be 
discounted. These regions shift slightly between the apo-, binary, and ternary 
structures, presumably to accommodate the glycopeptide at various stages of 
shuttling into the active site. It is therefore most likely that the production of 
novel sites of sulfonation in the glycopeptide substrate would be possible, but 
would require alteration of not only V3, but also changes in V1 and V2 as 
well. However, based on the observed interactions in the TEG12 structures, 
the possibility of generating a novel sulfotransferase by specific alterations in 
the variable loops seems an exciting and distinct possibility. 
3.5 Materials and Methods 
3.5.1 TEG12 Expression and Purification  
TEG12 was cloned and expressed as previously described (Banik and 
Brady 2008).   Briefly, teg12 was amplified (30 cycles of 95 °C for 30 s, 60 °C 
for 30 s, and 72 °C for 90 s; FailSafe system from Epicentre) from eDNA 
cosmid clone D30 using the following primers: 
TEG12FWD(BclI):GCGCTGATCAATGAACGGAATTCGATGG, 
TEG12REV(HindIII):GCGCAAGCTTTCCTTAACCGGCATACCCGTA.  
Restriction enzyme sites used for cloning are shown in bold.  The resulting 
product was doubly digested with BclI and HindIII and subsequently ligated 
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into pET28a, which had been BamHI/HindIII doubly digested.  The resulting 
construct was then transformed into E. coli BL21(DE3) for protein 
expression.  Expression cultures were grown to OD600=0.6, followed by IPTG 
induction, and overnight growth at 20 °C.  The culture was pelleted by 
centrifugation (3,200 x g for 30 min), the supernatant was discarded, and the 
cell pellet was resuspended in 40 mL lysis buffer [50 mM HEPES, pH 7.5, 0.5 
M NaCl, 5% (vol/vol) glycerol, 20 mM imidazole, pH 8, 10 mM β-
mercaptoethanol and 0.5% (vol/vol) Triton X-100].  The resuspended cell 
pellet was lysed by sonication, and the insoluble portion was removed by 
centrifugation (15,000 x g for 30 min).  The cleared cell lysate was incubated 
with 1 mL Ni-NTA resin for 15 min.  The slurry was loaded onto a column, 
allowed to empty by gravity flow, washed with 40 mL lysis buffer, and finally 
washed with 40 mL wash buffer [50 mM HEPES, pH 7.5, 0.5 M NaCl, 5% 
(vol/vol) glycerol, 20 mM imidazole, pH 8.0, and 10 mM β-mercaptoethanol].  
The protein was eluted by the addition of 15 mL of elution buffer [50 mM 
HEPES, pH 7.5, 0.5 M NaCl, 5% (vol/vol) glycerol, 125 mM imidazole, pH 8, 
and 10 mM β-mercaptoethanol].  No attempt was made to remove the vector 
derived 6X-histidine tag, resulting in a TEG12 protein plus 34 additional 
residues N-terminal to the start methionine.  Protein was concentrated using 
Vivascience Vivaspin 30,000 MWCO ultrafiltration concentrators, and was 
buffer exchanged 3 times into protein buffer [200 mM NaCl, 20 mM HEPES, 
pH 7.5, 5% glycerol, and 1 mM DTT].  
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3.5.2 TEG12 Crystallization   
Concentrated protein was centrifuged at 14,000 rpm (4 °C, 30 min) in a 
microcentrifuge to remove any insoluble material prior to crystallization.  All 
crystals were grown using the hanging drop vapor diffusion method.  Initial 
TEG12-apo crystals were obtained by mixing 1 µl of protein (7.5 mg/ml in 
protein buffer) with 1 µl of reservoir solution (1.0 M sodium citrate, 0.1 M 
sodium cacodylate, pH 6.5, JCSG core III-48, Qiagen) over a 500 µl reservoir.  
Blade-like crystals grew overnight at 22 °C and reached a maximal size of 
400 µm X 50 µm X 20 µm in approximately one week.  To improve crystal 
thickness, TEG12-apo crystals were optimized by microseeding, in addition to 
mixing 1 µl of protein at 7.5 mg/ml with 0.5 µl of reservoir and 0.5 µl of Silver 
Bullet reagent 29 (Hampton Research).  A component of the Silver Bullet 
screen, aspartame, was modeled into the PAPS binding site of one of the 
monomers of the TEG12 dimer.  Crystals were soaked in a 20 µl drop 
containing reservoir solution plus 10% ethylene glycol.  The drop was allowed 
to dehydrate by exposure to open air at room temperature for approximately 
5 hours before flash cooling the crystals in liquid ethane.   
TEG12-ternary crystals were co-crystallized at 4 °C in the presence of 
2 mM PAP and 1 mM teicoplanin aglycone.  TEG12 was first concentrated to 
20 mg/ml in protein buffer.  The protein was then diluted 1:1 with 50 mM 
CHES, pH 9.1, 2 mM teicoplanin aglycone, 4 mM PAP, achieving a final 
concentration of 10 mg/ml TEG12 in 0.5X protein buffer, 25 mM CHES, pH 
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9.1, 1 mM teicoplanin aglycone, 2 mM PAP.  1 µl of protein was mixed 1:1 
with reservoir solution (0.2 M ammonium acetate and 20% w/v PEG 3350, 
JCSG, core I-25, Qiagen).  Crystals appeared in 2-3 days and grew to a 
maximal size of 100 µm X 50 µm X 50 µm in approximately 1 week.  These 
crystals were of an irregular chunk-like morphology and had cracks 
throughout.  Crystals were cryo-protected by quickly dunking in reservoir 
solution plus 15% ethylene glycol and were flash cooled in liquid nitrogen. 
TEG12-binary crystals were co-crystallized at 4 °C in the presence of 1 
mM teicoplanin aglycone.  Similar to TEG12-ternary crystallization, the 
protein was first concentrated to 20 mg/ml in protein buffer, then diluted to 
10 mg/ml with 50 mM CHES, pH 9.1, 2 mM aglycone  (final 0.5X protein 
buffer, 25 mM CHES, 1 mM teicoplanin aglycone).  1 µl of protein solution 
was mixed with 1 µl of reservoir solution (2.0 M sodium formate, 0.1 M 
sodium acetate, pH 4.6, JCSG core III-85, Qiagen).  Cubic crystals grew 
between 2 and 3 weeks, and were approximately 50 µm X 50 µm X 50 µm.  
Crystals were soaked in 6.0 M sodium formate, 0.1 M sodium acetate, pH 4.6, 
1 mM teicoplanin aglycone overnight, prior to flash cooling in liquid nitrogen. 
3.5.3 Data Collection and Structure Solving   
All data sets were reduced and scaled using the HKL2000 package 
(Otwinowski and Minor 1997).  Data for TEG12-apo crystals were collected at 
the NSLS, beamline X29A.  All but one of the crystals screened diffracted 
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poorly to approximately 4 Å resolution.  The crystal from which the 2.91 Å 
dataset was collected rotated briefly out of the cryostream, and thereby had 
gone through a room temperature annealing cycle of several seconds.  
Diffraction from this crystal was dramatically improved compared with other 
crystals taken from the same drop.  Data for TEG12-apo was reduced and 
scaled in space group C2221.  Phase information was obtained by molecular 
replacement using the program Phaser and StaL (GenBank accession 
number AAM80529, PDB code 2OV8), devoid of all flexible loops, as the 
search model (McCoy, Grosse-Kunstleve et al. 2007).  The initial molecular 
replacement model was refined against the TEG12-apo dataset using rigid 
body refinement in Refmac (Murshudov, Vagin et al. 1997).  Additional 
features of the map were enhanced through density modification, and 2-fold 
ncs averaging in CNS (Brunger, Adams et al. 1998; Brunger 2007).  The 
model was rebuilt manually using the program Coot (Emsley and Cowtan 
2004).  Full restrained refinement was carried out using the 
translation/libration/screw model in Refmac, with the addition of hydrogen 
atoms, converging to a final Rwork and Rfree of 21.70 and 27.05, respectively 
(Winn, Isupov et al. 2001).  NCS restraints were not used during refinement.  
The final model comprises residues 1-129, 136-203, and 251-285 for monomer 
A, and 1-27, 42-128, 137-210, 247-285 for monomoer B.  The TEG12-apo 
model was used as a molecular replacement model for all subsequent 
structures. 
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TEG12-ternary and TEG12-binary data sets were collected at the APS, 
microfocus beamline 24-IDE.  TEG12-ternary data was reduced and scaled in 
space group P212121.  TEG12-binary was scaled in space group I212121.  The 
crystal structure of glycopeptide aglycone A-40926 was used as a starting 
point to generate a restraint definition file for teicoplanin aglycone using the 
program Phenix Elbow (Schafer, Schneider et al. 1996).Geometry 
optimization was achieved using the semi-empirical quantum mechanical 
AM1 method.  TEG12-binary and TEG12-ternary models were refined using 
the translation/libration/screw model in Phenix Refine to a final Rwork and 
Rfree of 17.30 and 22.61, and 17.12 and 22.47, respectively (Winn, Isupov et al. 
2001).  The final TEG12-binary model comprises residues 1-129, 135-216, and 
247-285.  The final TEG12-ternary model comprises residues 1-215, 220-224, 
and 231-285 for monomer A, and residues 1-129, 136-224, and 240-285.  All 
structures were validated using the Molprobity server from the Richardson 
laboratory at Duke University (Davis, Leaver-Fay et al. 2007). 
3.5.4 Site-Directed Mutagenesis   
TEG12 point mutants were generated using the “megaprimer” method, 
with slight modifications (Sarkar and Sommer 1990).  Oligonucleotide 
primers were designed for each mutant (Table 3), and a megaprimer was 
generated by PCR amplification from the TEG12/pET28a construct using the 
Pfx Accuprime System (Invitrogen), the relevant mutant oligonucleotide 
primer, and either the T7 promoter (for mutations at residues 9-108) or the 
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T7 terminator (for mutations at residues 167-251) as the second 
oligonucleotide primer, (30 rounds of amplification: 95 °C for 30 s, 55°C for 30 
s, 68 °C for 30 s).  The full length mutant TEG12 gene was amplified from the 
TEG12/pET28a construct, using the megaprimer, which then contained the 
bases that code for the specific mutant residue, and either the T7 terminator 
(for mutations at residues 9-108) or the T7 promoter (for mutations at 
residues 167-251) as the second oligonucleotide primer (30 rounds of 
amplification: 95 °C for 30 s, 55 °C for 30 s, 68 °C for 80 s).  Full-length 
mutant amplicons were then sequentially digested with BamHI and HindIII, 
and subsequently ligated into BamHI/HindIII doubly digested pET28a. 
Ligated constructs were transformed into E. coli EC100 (Epicentre), and 
sequenced to identify successfully mutated constructs.  Mutant constructs 
containing the desired point mutation were then transformed into E. coli 
BL21 (DE3) for protein expression.  
3.5.5 Mutant TEG12 Expression and Purification   
Mutant proteins were expressed and purified in a manner similar to 
the native TEG12, except on a reduced scale.  100 mL overnight expression 
cultures were pelleted and resuspended in 4 mL lysis buffer.  After sonication 
to lyse the cells, the crude lysates were centrifuged to remove insoluble 
material (10 min at 15,000 x g).  The cleared lysates were incubated with 100 
µl Ni-NTA resin for 15 min.  The slurry was then loaded onto a column, 
allowed to empty by gravity flow, washed with 4 mL lysis buffer, followed by 
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a second wash with 4 mL wash buffer.  The protein was eluted by the 
addition of 1.5 mL elution buffer.  All TEG12 mutants used in activity assays 
appeared to be homogeneous by polyacrylamide gel electrophoresis 
3.5.6 TEG12 Activity Assays 
All soluble TEG12 mutants were assayed for activity using the 
teicoplanin aglycone as a substrate.  50 µL reactions were run in duplicate, as 
follows: 15 mM HEPES, pH 7.5, 1 mM 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS), 0.1 mM DTT, 1.2 mM teicoplanin aglycone (in DMSO), and 500 ng 
purified protein in elution buffer.  Reactions were carried out at 30 °C for 
each of the four time points (10, 15, 20, 25 min), followed by heat inactivation 
at 99 °C for 10 min, and a further 10 min in an ice water bath.  Vmax and Km 
values were determined under the same reaction conditions using the 
teicoplanin aglycone as substrate (5 µM to 100 µM).  25 µL of each reaction 
was run on a Waters analytical HPLC system (C18 (4.6 x 150 mm)).  A linear 
gradient (1.5 ml/min) was run from an initial condition of 95:5 20 mM 
ammonium acetate:acetonitrile to 70:30 20 mM ammonium 
acetate:acetonitrile over twenty minutes.  The area under the UV peak 
(Diode Array, 240 nm-400 nm) was determined for both the monosulfated 
product and the teicoplanin aglycone substrate at each time point. The 
percent substrate conversion for duplicate time points was averaged.  The 
slope of the graph derived from the four time points for TEG12 and each 
91 
 
mutant was then determined.  Relative activity of each mutant is reported as 
a percent of the slope for wild-type TEG12.  
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CHAPTER 4 
4 Selective Enrichment of eDNA Libraries for 
Clones Rich in Secondary Metabolism Genes 
4.1 Chapter Summary 
 Chapter 4 outlines the process by which the AB and AZ eDNA-derived 
cosmid mega-libraries, discussed in chapter 2, were enriched for genes 
associated with secondary metabolite biosynthetic gene clusters.  The 
selection-based strategy used to achieve this enrichment involved the eDNA-
mediated complementation of the E. coli enterobactin biosynthetic pathway 
(entA-F), which is responsible for siderophore production and is required for 
growth under iron-limiting conditions.  The enterobactin pathway gene entD 
encodes for a 4’-phosphopantetheinyltransferase (PPtase) enzyme that carries 
out the post-translational modification of EntB and EntF, the non-ribosomal 
peptide synthetases (NRPSs) that biosynthesize the enterobactin backbone. 
When entD was knocked out of E. coli, the resulting mutant strain was 
unable to grow on iron-deficient media (modified M9 media).  However, 
complementation of this mutant strain by exogenous PPtases encoded on 
eDNA-derived cosmids was able to successfully rescue E. coli by restoring 
enterobactin biosynthesis.  As is the case with entD and the enterobactin 
pathway from E. coli, PPtases from Gram-negative organisms are frequently 
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clustered with the biosynthetic gene clusters upon which they act.  
Consequently, this selection strategy is able to enrich eDNA megalibraries 
for clones harboring secondary metabolite biosynthetic genes in addition to 
the functional PPTase activities through which such clones are selected.  
Next-generation (454) pyrosequencing of eDNA library clones selected for in 
this manner was then used to compare the “secondary metabolism” contents 
of enriched versus non-enriched library clones.  This analysis demonstrated 
an increase in the secondary metabolism content of enriched library clones 
compared to randomly selected (non-enriched) library clones.  This increase 
corresponded to over an order of magnitude rise in the percentage of 
nucleotide bases derived from NRPS, Polyketide synthase (PKS), or PPtase 
genes found within the enriched library.  This preliminary demonstration of 
the efficacy of this enrichment strategy is a promising indication that such 
methods might be used in the future to quickly and easily obtain novel 
secondary metabolites from eDNA mega-libraries of over ten million unique 
cosmid clones. 
4.2 Introduction 
eDNA-derived cosmid mega-libraries possess enormous biosynthetic 
potential. However, bulk eDNA samples represent pools of bacterial genomic 
DNA and are therefore undoubtedly dominated by genes encoding proteins 
involved in primary metabolic functions. Given the enormous amount of 
genetic information contained in a 10+ million-member eDNA-derived cosmid 
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library (~100,000 bacterial genomes), the identification of novel biosynthetic 
information from the milieu possess a rather arduous task. If, however, the 
cosmid clones containing genes likely to be involved in secondary metabolite 
biosynthesis could be isolated from the rest, a more systematic, exhaustive 
examination of the remaining clones could be carried out. The strategy 
described in this chapter utilizes a complementation strategy to enrich an 
eDNA cosmid mega-library for clones likely to be rich in secondary metabolite 
biosynthetic enzymes. 
This enrichment strategy focuses on the enrichment of libraries for 
clones containing two of the more common classes of secondary metabolite 
biosynthetic enzymes, non-ribosomal peptide synthetases (NRPSs) and 
polyketide synthases (PKSs). These enzymes are post-translationally 
modified by the action of 4’-phosphopantetheinyltransferases (PPtases), 
whose action is essential to the maturation of NRPSs and PKSs, producing 
active enzyme via the covalent attachment of a 4’-phosphopantetheinyl group 
to a conserved serine residue in the peptidyl carrier protein (PCP) of NRPSs 
or the acyl carrier (ACP) of PKS proteins (Macpherson, Manning et al.). 
NRPSs and PKSs are capable of biosynthesizing complex small molecules 
from simple starting materials. The genes encoding PPtases are often found 
either internal to or in close proximity to the NRPS and PKS systems they 
modify. This proximal linkage was essential to the selection of PPtases as a 
95 
 
target for our complementation strategy to enrich our metagenomic libraries 
for NRPS and PKS enzymes. 
Enterobactin (37) is an NRPS-derived siderophore produced by E. coli 
(Figure 18) (Liu, Duncan et al. 1989). In addition to the NRPS biosynthetic 
genes entE, entB, and entF contained in the enterobactin biosynthetic gene 
cluster, there is a cluster-specific PPtase, entD. The removal of entD from E. 
coli strain EC100, which produces enterobactin as its sole siderophore, 
abolishes the ability of the entD-minus strain to produce this siderophore and 
results in the inability to grow on iron deficient media. By targeting entD, it 
becomes possible to select for eDNA-derived cosmid clones capable of 
complementing the enterobactin pathway, generally through the expression 
of an active, exogenous PPtase (Figure 18). The selection of clones based on 
the presence of an expressed PPtase allows us to take advantage of the 
commonly observed proximal linkage of genes encoding PPtases and genes 
encoding NRPSs and PKSs to enrich a library for two of the most common 
classes of enzymes seen in secondary metabolite biosynthesis.  
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Figure 18: Enterobactin biosynthesis and complementation strategy  
A): 4’-phosphopantetheinylation of PKSs and NRPSs (on a conserved serine on the ACP or 
PCP, respectively) leads to the activation of these enzymes. B): Enterobactin (37) is an NRPS 
derived siderophore, utilized by E. coli in iron scavenging under low iron conditions. C): 
Production of enterobactin in E. coli is disrupted by knocking out the native PPtase, entD. 
entD is responsible for the maturation of the NRPS system, which biosynthesizes 
enterobactin.  
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4.3 Results 
4.3.1 Construction of an entD- E. coli strain for Complementation and 
Enrichment of an eDNA-derived Cosmid Mega-library  
 A PPtase-deficient E. coli strain (E. coli EC100 ∆entD) was generated 
using RecET recombination (Zhang, Muyrers et al. 2000). E. coli EC100 
∆entD (hereafter referred to as EC-∆entD) does not produce enterobactin, and 
is thus incapable of growth on iron deficient media. EC-∆entD was then used 
to enrich an eDNA-derived cosmid megalibrary (constructed in either of two 
cosmid vectors (pWEB or pWEB-TNC, Epicentre) for clones with the ability 
to grow on iron-deficient “entD complementation selection” media (see 
Materials and Methods). 
Two cosmid mega-libraries, each containing in excess of 10,000,000 
clones, were subjected to the PPtase-based enrichment strategy described 
above. Both libraries were transformed into EC-∆entD and plated directly 
onto iron-deficient “entD complementation selection” media plates. 
Approximately 1 of every 2,500 library clones grew on the low-iron selection 
media. After a second round of selection, approximately 1 in every 20 library 
members was capable of growth on the selection media, representing a 125-
fold enrichment over the first round of selection. An additional round of 
selection on low iron media produced a collection of clones from which 50-90% 
were independently proven to be capable of complementing the entD 
knockout mutation. 
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4.3.2 Enriched libraries contain an abundance of NRPS and PKS 
biosynthetic genes 
To examine the relative success of the entD complementation 
enrichment strategy, an approximate (4.5 Mb) genome equivalent of cosmid 
clones was sequenced from the enriched library along with a similar 
equivalent from randomly selected cosmid clones from the original eDNA 
library used in the enrichment process. Cosmids were sequenced (454 
pyrosequencing, Roche), and assembled contigs greater than 30 kb in length 
were submitted to the RAST online server for automated annotation (Aziz, 
Bartels et al. 2008). These two data sets were then analyzed for the presence 
of putative NRPSs and PKSs, as well as for genes encoding PPtases (Figure 
19). A simple qualitative analysis, such as that displayed in Figure 19, 
indicated that this enrichment strategy had been successful at recovering 
eDNA clones rich in secondary metabolite biosynthetic enzymes. All predicted 
NRPS and PKS enzymes over 3 kb were then submitted as BLASTP search 
queries against all non-redundant protein sequences, and bacterial phyla 
predictions were made based on the consensus of top scoring BLAST hits. The 
results of this analysis are summarized in Table 5. 
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Figure 19: ORF prediction maps for Non-enriched (RANDOM) and Enriched library 
clones. 
Predicted ORF maps from both sequencing runs; Non-enriched (i.e., random)  (left), Enriched 
(right). Genes filled red are putative NRPSs and/or PKSs that are longer than 3,000 
nucleotides. Genes filled yellow are putative 4’-phosphopantetheinyltransferases. 
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Table 5: A comparison of the fractional biosynthetic contents (% total nucleotides 
belonging to NRPS/PKS genes) of enriched library clones, non-enriched library 
clones and select bacterial genomes.   
Sample Total NTs % NRPS/PKS 
Enriched 4544371 27.31 
Non-Enriched 4688540 0.88 
Escherichia coli UTI89 5065741 0.54 
Bacillus cereus G9842 5387334 0.14 
Pseudomonas aeruginosa LESB58 6601757 0.34 
Salinispora tropica CNB-440 5183331 0.53 
Bacteroides fragilis YCH46 5277274 0.02 
Streptomyces coelicolor A3(2) 9023530 2.31 
Prochlorococcus marinus MIT 9303 2682675 0.28 
 
In order to quantitatively assess the success of this enrichment 
strategy, the percentage of nucleotides contained in predicted NRPS and PKS 
enzymes (i.e., the “biosynthetic content”) was calculated for both the enriched 
and non-enriched data sets and several sequenced genomes from a range of 
different bacteria (Table 5). As can be seen in Table 5, the percentage of 
nucleotides from most sequenced bacterial genomes corresponding to NRPS 
and PKS genes is below 1%, with the notable exception being the 
Streptomyces coelicolor A3(2) genome, which encodes the PKS derived 
antibiotic actinorhodin and contains over a dozen cryptic secondary 
metabolite biosynthetic gene clusters. Remarkably, the genomic equivalent 
from our enriched library has a biosynthetic content that is over an order of 
magnitude greater than the Streptomyces coelicolor A3(2) genome. 
Furthermore, compared to most sequenced bacterial genomes and to our 
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randomly selected (non-enriched) genome equivalent, the disparity in 
biosynthetic content is closer to two orders of magnitude. This significant 
level of enrichment should allow for a much more extensive examination of 
the select group of enriched library clones than would ever be feasible with 
eDNA megalibraries containing 10+ million clones. 
4.3.3 Cultivation of Clones from Enriched Library 
 To evaluate the potential of enriched eDNA library clones to 
heterologously produce clone specific secondary metabolites in E. coli, 1152 
unique clones from the enriched library were cultured in iron-deficient entD 
complementation selection medium to ensure that clone-specific PPtases were 
actively expressed as functional enzymes. It is logical that such conditions 
should increase the potential for expression of clone-specific small molecule 
biosynthetic gene clusters. A subset (576) of these clones was also cultured in 
LB medium. Individual cell cultures of these 576 clones were extracted with 
ethyl acetate under both neutral (unadjusted) and acidic (pH 3-4) conditions, 
while cultures of the remaining 576 clones were extracted only at neutral 
(unadjusted) pH. Analysis of these 1152 E. coli based heterologous expression 
cultures did not yield clone-specific metabolites as determined by TLC and 
LCMS. 
4.3.4 Phenotypic Screening of Enriched Libraries 
 Enriched libraries were plated onto both LB and entD 
complementation selection medium to attempt to identify clones, which 
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possessed the ability to produce clone-specific metabolites, demonstrated by 
the generation of a high-yield phenotype (pigmentation, altered colony 
morphology, or antibiosis). Clones were plated at a titer, which would yield 
distinct, well-spaced colonies (300-500 clones on a 150 mm diameter plate). 
These plates were incubated for four days, at which point they were 
examined for clones displaying pigmentation or altered colony morphology. 
To identify clones displaying antibiosis, the plates were overlayed with one of 
three assay strains. After incubation for an additional two days, the plates 
were examined for zones of growth inhibition in the various assay strains. No 
clones were identified from the entD complementation selection medium 
screen that produced clone-specific metabolites. One clone, which was 
identified from a screen on LB media, produced a clone-specific metabolite. 
This clone, which did not grow on the entD complementation selection 
medium was, based on HPLC-MS, determined to be producing N-acyl 
tyrosines. One major hurdle, which was not overcome, was the generation of 
a small zone of growth inhibition by every clone, which grew on the entD 
complementation selection medium when grown in the presence of B. subtilis. 
This impediment is one that must be overcome in future work, as this 
bacterium is very commonly used for phenotypic screening due to its high 
sensitivity to many test compounds. 
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4.4 Discussion and Future Directions 
 The eDNA-derived cosmid mega-libraries constructed for the 
metagenomics efforts described in chapter 2 contain too many individual 
members to exhaustively examine each for the production of novel, clone-
specific small molecules. The work presented in this chapter outlines a means 
by which 10+ million cosmid clones can be sorted (i.e., “selected for” or 
“enriched in”) to identify several thousand with a very high likelihood of 
containing secondary metabolite biosynthetic machinery. Although the 
examination of several thousand individual clones in pure culture is not a 
trivial task, it is logistically much more possible than a similar examination 
of over ten million clones.  
 The enrichment strategy described in this chapter has obvious 
limitations. First and foremost, the selective-enrichment process is carried 
out in E. coli, which is predicted to be limited in terms of the expression of 
eDNA-derived genes (Gabor, Alkema et al. 2004). While being one of the most 
widely used heterologous expression hosts in the majority of functional 
metagenomic efforts, the development of additional heterologous hosts that 
are better suited for the production of secondary metabolites is likely to 
result in more favorable outcomes. 
The bacterial phyla predictions that were made for each NRPS/PKS 
clone sequenced from the enriched and non-enriched libraries indicate a 
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major need for more taxonomically diverse hosts for the selective enrichment 
process.  The majority of predicted NRPS and PKS enzymes from the 
enriched set of clones belong to either cyanobacterial or proteobacterial 
sources (Table 6). However, as E. coli is a Gram-negative member of the γ-
Proteobacteria, it is perhaps not surprising that the majority of the NRPSs 
and PKSs selected for by this E. coli-based process derive from Proteobacteria 
or members of the Gram-negative Cyanobacteria. Similar complementation 
strategies in bacteria that are taxonomically distant from the Proteobacteria 
would presumably result in a vastly different yield of recovered NRPSs and 
PKSs. 
Table 6: Phylum-level source predictions for eDNA-derived biosynthetic genes.  
Phyla PPtases PPtases  NRPS/PKS  NRPS/PKS 
  ENRICHED RANDOM  ENRICHED RANDOM 
Cyanobacteria 78  131 3 
Proteobacteria 16 1 71 1 
Verrucomicrobia 7    
Actinobacteria 6  2  
Bacteroidetes 1  3  
Chloroflexi 1    
Acidobacteria 1    
Firmicutes     4   
 
One additional observation that must contribute heavily to future 
endeavors with this system is that many of the possible pathways identified 
using this specific enrichment strategy will undoubtedly be truncated due to 
the use of cosmid-based libraries housing 35-40 kb eDNA inserts. One 
possible solution to this problem is the recovery of overlapping cosmid clones, 
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as was done for the recovery of intact glycopeptide biosynthetic gene clusters 
in chapter 2. Alternatively, one could imagine creating libraries with 
significantly larger eDNA inserts. Larger insert libraries, such as those 
constructed using Bacterial Artificial Chromosomes (BAC) are notoriously 
difficult to build, however addressing this issue may be essential to the 
expansion and eventual success of this strategy. 
4.5 Materials and Methods 
4.5.1 Library Enrichment 
EC-∆entD was constructed using Rec/ET recombineering (Zhang, 
Muyrers et al. 2000). For library enrichment, pools of two separate eDNA-
derived cosmid mega-libraries, each containing in excess of ten million 
individual clones, were transformed into EC-∆entD. These mega-libraries 
were constructed using two cosmid vectors: pWEB and pWEB-TNC 
(Epicentre). Both libraries were first transformed into the entD- E. coli strain, 
outgrown for 1 h at 37°C in SOC, and then plated onto an LB medium plate 
containing either 30 µg/mL kanamycin (pWEB) or 12.5 µg/mL 
chloramphenicol (pWEB-TNC). These plates were then scraped after the 
addition of liquid LB and stored away as a glycerol stock. This glycerol stock 
was then used as an inoculum for a 50 mL LB media culture, which was 
grown to an OD600 ~ 0.5. The culture was then pelleted, washed three times 
with sterile M9 media, and plated directly onto iron-deficient entD 
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complementation selection media (M9 media supplemented with 1 g/L 
casamino acids, 10 µM thiamine-HCl, 100 µM 2,2-dipyridyl, and either 30 
µg/mL kanamycin (pWEB) or 12.5 µg/mL chloramphenicol (pWEB-TNC)) 
with 15 g/L agar and antibiotic selection, as well as onto LB agar with 
antibiotic selection to determine the titer of the enrichment. Plates were kept 
at 37°C, and colonies appeared after 12-16 h. Sterile M9 media was added to 
the selection plates after 36-48 hours, and the plates were scraped and used 
to inoculate an overnight LB culture containing appropriate antibiotic 
selection. This culture was grown overnight at 37°C and then used as an 
inoculum for a 50 mL LB culture, which was grown to an OD600 ~ 0.5, washed 
three times with sterile M9, and plated yet again onto iron-deficient entD 
complementation selection media containing 15 g/L agar. The plating on entD 
complementation selection media, scraping, growing overnight, growing to 
mid-log phase, washing, and re-plating represented one round of enrichment. 
A total of three enrichment rounds were carried out.  
4.5.2 Sequencing of Clones from Enriched and Non-enriched 
Libraries 
Individual colonies from the selective enrichment were chosen for 
sequencing following the final round of the enrichment process. Colonies were 
picked from plates after incubation at 37°C for 36 hours. These colonies were 
cultured overnight in LB medium, and mini-prepped (Qiagen). eDNA-derived 
cosmids for 500 individual clones were sequenced using 454 pyrosequencing 
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(Roche). These colonies were considered representative of the enriched 
library. For sequencing of the un-enriched library, pools from the AB and AZ 
libraries were plated out at a sufficient titer to yield well-spaced individual 
colonies. Colonies were cultured overnight in LB medium, and mini-prepped 
(Qiagen). 500 individual eDNA-derived cosmids were sequenced using 454 
pyrosequencing (Roche), representing the non-enriched (original) library. 
4.5.3 Bioinformatics Analysis of Cosmid Clones 
 126 contigs from both the enriched and the non-enriched 454 
sequencing data sets, each in excess of 30 kb, were chosen for bioinformatic 
analysis.  This quantity of sequencing information was roughly equivalent to 
a small-medium sized bacterial genome. Following an Open Reading Frame 
(ORF) prediction using the RAST server (Aziz, Bartels et al. 2008), all 
predicted PKSs and/or NRPSs in excess of 3 kilobases were assigned as 
“PKSs or NRPSs” and are depicted in Figure 19. Predicted PPtases are also 
shown in Figure 20. A calculation was then made to express the fraction of 
nucleotides from each 126 contig data set that were contained in predicted 
PKSs, NRPSs, and PPtases as a percentage of the total nucleotides sequenced 
from each data set. A similar calculation was made for a few select bacterial 
genomes, representing species found across various major phyla. This data is 
reported in Table 5. 
 A phylogenetic analysis of the PPtases identified from the enriched 
library was then performed using a BlastP analysis.  Probable phylum-level 
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source predictions were made for each individual PPtase based on origins of 
the top Blast hit(s). A tabulation of this analysis is found in Table 6.  
4.5.4 Culture of Individual Cosmid Clones  
Individual E. coli clones from the final round of library enrichment 
were cultured and extracted with organic solvent to determine if this 
enrichment technique was identifying clones with the immediate potential to 
produce clone-specific secondary metabolites. Following the final stage of 
library enrichment, 1152 colonies were picked and used to inoculate 96 well 
culture plates containing LB medium. These plates were incubated overnight 
at 37°C. An equal volume of 30% sterile glycerol was added to each well, 
mixed, and stored at -80°C. 25 mL of culture media (either iron-deficient entD 
complementation selection medium or LB medium) was added to 50 mL 
conical tubes. Individual tubes were inoculated with a single colony from the 
stored glycerol stocks (their caps attached loosely for air exchange) and 
placed at 30°C and 200 rpm orbital shaking for 4 days. After 4 days, tubes 
were removed from the incubator and mixed with an equal volume (~ 20 mL) 
of ethyl acetate.  
The first 576 cultures were grown both in LB and in iron-deficient entD 
complementation selection media, and were extracted both under neutral 
(unadjusted) pH and under acidic (adjusted to 3-4 using 10% HCl) pH. A 
negative control of E. coli EC100 transformed with pWEB-TNC was added to 
each round of cultures. Extractions were centrifuged briefly (3 min) at ~3,000 
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x g and the ethyl acetate fraction was decanted into glass tubes for vacuum 
drying. Dried samples were resuspended in methanol (~0.5 mL) and 
transferred to 1 dram glass vials to concentrate the sample for TLC. Dried 
samples were resuspended in 40 µL of methanol (acidified for adjusted 
samples) and 5 µL was loaded onto a TLC plate. These plates were run in 
90:10 chloroform:methanol and assayed under UV-light (365 nm) and by 
crystal iodine staining. E. coli EC100 transformed with pWEB-TNC was used 
as a control culture. 
Cultures displaying possible clone-specific metabolite production were 
subjected to LCMS using a Waters analytical HPLC system (C18 (4.6 x 150 
mm)). Initial conditions were 90:10 water containing 0.1% formic 
acid:methanol, followed by a linear gradient from 90:10 to 0:100 over 20 
minutes, followed by 5 minutes at 0:100. Based on the observed background 
for the LB cultures and cultures extracted under acidic conditions, the second 
576 cultures were grown exclusively in iron-deficient entD complementation 
selection media and extracted under neutral (unadjusted) pH.  
4.5.5 Phenotypic Screening of Enriched Libraries 
 A glycerol stock of each enriched library was used as an inoculum for a  
50 mL LB media culture. This culture was grown at 37°C with 200 rpm 
shaking until the OD600 reached 0.5. The culture was then washed three 
times with 50 mL of sterile M9 media and plated. A titer of 300-500 clones on 
a 150 mm diameter plate was achieved by plating 5, 10, and 50 µL of a 10-4 
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serial dilution. Cultures were plated on solid entD complementation selection 
media with antibiotic selection (M9 media supplemented with 1 g/L casamino 
acids, 10 µM thiamine-HCl, 100 µM 2,2-dipyridyl, 15 g/L agar) and 100 
µg/mL ampicillin and LB agar with 100 µlgmL ampicillin.  These plates were 
incubated overnight at 30°C, removed to room temperature, where they 
remained for a following three days. The plates were then examined for 
clones displaying pigmentation or altered colony morphology. To identify 
clones displaying antibiosis, the plates were overlayed with E. coli BAS849, 
B. subtilis 1E9, or Saccharomyces cerevisiae W303. 100 plates each were 
overlayed for each strain. Overlay was carried out using top agar (LB or entD 
complementation selection media with 5 g/L agar) inoculated with a 10-4 
dilution of an OD600 = 0.5 of each assay strain. After incubation for an 
additional two days at room temperature, the plates were examined for zones 
of growth inhibition in the various assay strains.  
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CHAPTER 5 
5. Future Directions 
5.1 BAC Libraries 
One of the largest obstacles to the recovery of intact secondary 
metabolite biosynthetic gene clusters from eDNA-derived cosmid libraries is 
the low probability (for medium sized gene clusters) or complete inability (for 
very large gene clusters) of many pathways to be contained on an individual 
cosmid due to size constraints. Additionally, even if one recovers a complete 
pathway contained on overlapping cosmid clones, the reconstruction of a 
contiguous pathway on a single linear vector has been, until recent 
developments with transformation associated recombination (TAR) in yeast, 
technically very difficult (Kim, Feng et al. 2010). An obvious solution to this 
problem is to simply construct larger insert libraries. If individual clones 
contained over 100 kilobases of contiguous eDNA, many of the difficulties 
associated with cosmid-based heterologous expression studies would be 
overcome. One strategy that has been used to construct large insert gDNA 
libraries involves the construction of bacterial artificial chromosomes or 
BACs, which have been reported to stably maintain over 300 kilobases of 
DNA (Tao and Zhang 1998).  
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One problem with the construction of BAC libraries for metagenomics 
research has been the technical inability to produce large collections of BAC 
clones. Initial studies yielded libraries with at most tens of thousands of 
clones (Rondon, August et al. 2000). Thus, it was hypothesized that one must 
sacrifice overall metagenomic coverage to gain access to larger contiguous 
pieces of DNA. Recent advancements in BAC cloning have led to the 
production of libraries containing in excess of one million clones (Magbanua, 
Ozkan et al. 2011). Additional internal observations in the Brady lab have 
determined that using desert soils, which contain less of the organic 
substances (humates, etc.) found in richer soils collected in eastern temperate 
environments, cosmid cloning efficiency can be increased by orders of 
magnitude. Therefore, it seems likely that the production of multi-million 
member eDNA-derived BAC libraries from soil bacteria is an inevitablilty. 
Such advancements will increase the rate with which large pathways are 
identified and used successfully in downstream heterologous expression 
experiments. 
5.2 eDNA-derived Cosmid Libraries Hosted in Streptomyces 
sp. 
 Much of the heterologous expression of eDNA-derived secondary 
metabolite biosynthetic gene clusters has been carried out in Streptomyces sp. 
(Banik and Brady 2008; King, Bauer et al. 2009; Bauer, King et al. 2010; 
Feng, Kim et al. 2010). Streptomyces produces many of the secondary 
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metabolites that have been identified using culture-based methods 
(Buckingham 1994). Creating an eDNA-derived cosmid library and 
transferring the entire library to various Streptomyces sp. would open up a 
number of different avenues in terms of metagenomics research. First, with 
the possible expansion of enrichment strategies such as described in chapter 
4 to Gram-positive species, it would seem only natural to transfer a library 
enriched in a Gram-positive host into representatives of this prolific small 
molecule producing genera of bacteria. Additionally, functional metagenomics 
experiments could be carried out, where colonies from multiple million-
member libraries could be assayed for phenotypes commonly associated with 
the production of clone-specific metabolites. Much smaller metagenomic 
libraries have already been hosted in Streptomyces, with some success (Wang, 
Graziani et al. 2000). However, the expansion from just over a thousand 
member library to a greater than ten million member library will 
undoubtedly increase the productivity of a strategy that is the natural 
crossroads of multiple avenues. 
5.3 Large-scale Sequencing Efforts 
The discovery of bioactive small molecules using metagenomic methods 
will undoubtedly benefit greatly from future advances in sequencing 
technology that allow for the comprehensive sequencing of complex 
microbiomes (Chan, Hsu et al. 2008; Morozova and Marra 2008; Glass, 
Wilkening et al. 2010; Yang, Peng et al. 2010), as well as from increasing our 
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understanding of the expression barriers encountered by foreign DNA in 
model laboratory grown bacterial hosts (Wang, Isaacs et al. 2009; Komatsu, 
Uchiyama et al. 2010). The TerraGenome project was established in 2008 in 
an effort to bring together sufficient sequencing power to sequence the first 
complete soil microbiome (Vogel, Simonet et al. 2009). Although only a small 
number of compounds have been characterized to date using culture-
independent methods, these initial studies indicate that as yet uncultured 
bacteria are likely to be a rich source of previously unknown biologically 
active small molecules. 
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APPENDIX 
Table 7: Predicted ORFs for VEG pathway 
Protein length is given in amino acids (AA). 
 
VEG ORFs     
ORF 
Length 
(AA) Predicted Gene Product Glycopeptide Homolog AA% ID (Organism) Accession # 
1 319 Transcriptional Regulator Transcriptional Regulator 92%(A. orientalis) CAB45047.1 
2 104 Transcriptional Regulator Transcriptional Regulator 72%(A. orientalis) CAB45048.1 
3 415 Integral Membrane Antiporter 
Integral Membrane 
Antiporter 91%(A. orientalis) CAB45049.1 
4 356 Oxidoreductase Oxidoreductase 87%(A. orientalis) CAB45050.1 
5 693 ABC Transporter ABC Transporter 78%(A. orientalis) CAB45051.1 
6 2069 
Nonribosomal Peptide Synthetase 
Modules 1-2 NRPS 75%(A. orientalis) CAB45052.1 
7 1057 
Nonribosomal Peptide Synthetase Module 
3 NRPS 
73%(A. 
teichomyceticus) CAE53351.1 
8 4002 
Nonribosomal Peptide Synthetase 
Modules 4-6 NRPS 82%(A. orientalis) CAA11795.1 
9 1866 
Nonribosomal Peptide Synthetase Module 
7 NRPS 87%(A. orientalis) CAA11796.1 
10 382 P450 Monooxygenase OxyA OxyA 80%(A. orientalis) AEI58868.1 
11 356 P450 Monooxygenase OxyB OxyB 92%(A. balhimycina) CAA76548.1 
12 430 P450 Monooxygenase OxyC OxyC 87%(A. orientalis) AEI58870.1 
13 492 Halogenase Halogenase 94%(A. orienatlis) CAA11780.1 
14 390 Glycosyltransferase GtfA 69%(A. orientalis) CAA11774.1 
15 409 Glycosyltransferase GtfE 78%(A. orientalis) AAB49299.1 
16 351 Glycosyltransferase GtfC 68%(A. orientalis) AAB49294.1 
17 408 Methyltransferase Methyltransferase 87%(A. orientalis) CAA11777.1 
18 273 Methyltransferase None 56%(Frankia sp.) ECF83210.1 
19 379 Glycosyltransferase GtfA 
67%(A. 
teichomyceticus) CAE53349.1 
20 268 Deacetylase Deacetylase 
67%(A 
.teichomyceticus) CAE53355.1 
21 578 Mannosyltransferase Mannosyltransferase 
84%(A. 
teichomyceticus) CAE53356.1 
22 604 Mannosyltransferase Mannosyltransferase 
80%(A. 
teichomyceticus) CAE53356.1 
23 407 Transposase None 67%(Frankia sp.) EFC78751.1 
24 283 N-methyltransferase N-methyltransferase 69%(A. orientalis) CAA11779.1 
25 280 N-methyltransferase N-methyltransferase 55%(A. orientalis) CAA11779.1 
26 433 Transcriptional Regulator Transcriptional Regulator 92%(A. orientalis) CAA11790.1 
27 277 BHT Perhydrolase BhtA 96%(A. orientalis) CAA11784.1 
28 578 BHT Peptide Synthetase BhtB 94%(A. orientalis) CAA11773.1 
29 397 BHT Oxygenase BhtC 91%(A. orientalis) CAA11772.1 
30 358 Hydroxymandelate Synthase HmaS 91%(A. orientalis) CAA11761.1 
31 370 Hydroxymandelate Oxidase Hmo 90%(A. orientalis) CAA11762.1 
32 472 NDP-Hexose-2,3,-Dehydratase EvaA 90%(A. orientalis) CAA11763.1 
33 326 NDP-Hexose-4-Ketoreductase EvaD 86%(A. orientalis) CAA11764.1 
34 370 NDP-Hexose-3-Aminotransferase EvaB 93%(A. orientalis) CAA11782.1 
35 203 NDP-Hexose-3,5-Epimerase EvaE 82%(A. orientalis) CAA11781.1 
36 379 Glycosyltransferase None 48%(M. echinospora) AF505622_8 
37 373 Dihydroxyphenylacetic Acid Synthase DpgA 95%(A. orientalis) CAA11765.1 
38 218 Enoyl-CoA Hydratase/Isomerase DpgB 86%(A. orientalis) CAA11766.1 
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39 431 Dihydroxyphenylacetyl-CoA Oxygenase DpgC 91%(A. orientalis) CAA11787.1 
40 268 Enoyl-CoA Hydratase/Isomerase DpgD 91%(A. orientalis) CAA11767.1 
41 357 Aldolase Aldolase 88%(A. orientalis) CAA11768.1 
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Table 8: Predicted ORFs for TEG Pathway 
Protein length is given in amino acids (AA). 
 
TEG ORFs     
ORF 
Length 
(AA) Predicted Gene Product Glycopeptide Homolog AA% ID (Organism) Accession # 
1 322 Transcriptional Regulator Transcriptional Regulator 86%(A. orientalis) CAB45047.1 
2 122 Chorismate Mutase None 80%(T.fusca YX) AAZ55245.1 
3 363 Prephenate Dehydrogenase 
Prephenate 
Dehydrogenase 89%(A. orientalis) CAA11792.1 
4 655 ABC Transporter ABC Transporter 
79%(A. 
teichomyceticus) CAE53357.1 
5 2078 
Nonribosomal Peptide Synthetase 
Modules 1-2 NRPS 79%(A. orientalis) CAA11794.1 
6 1070 
Nonribosomal Peptide Synthetase Module 
3 NRPS 
81%(A. 
teichomyceticus) CAE53351.1 
7 4133 
Nonribosomal Peptide Synthetase 
Modules 4-6 NRPS 82%(A. orientalis) CAA11795.1 
8 1865 
Nonribosomal Peptide Synthetase Module 
7 NRPS 83%(A. orientalis) CAA11796.1 
9 392 P450 Monooxygenase OxyA OxyA 
81%(A. 
teichomyceticus) CAE53359.1 
10 386 P450 Monooxygenase OxyD OxyD 79% (S. toyocaensis) AAM80534 
11 399 P450 Monooxygenase OxyB OxyB 
83%(A. 
teichomyceticus) CAE53361.1 
12 286 Sulfotransferase StaL 49%(S. toyocaensis) AAM80529.1 
13 277 Sulfotransferase StaL 54%(S. toyocaensis) AAM80529.1 
14 276 Sulfotransferase StaL 51%(S. toyocaensis) AAM80529.1 
15 411 P450 Monooxygenase OxyC OxyC 
84%(A. 
teichomyceticus) CAG15021.1 
16 494 Halogenase Halogenase 
86%(A. 
teichomyceticus) CAG15020.1 
17 444 Dyp-Type Peroxidase None 42%(M. nodulans) ACL56652.1 
18 583 Pyrrolo-Quinoline Quinone None 24%(M. maripaludis) ABX01476.1 
19 393 Arylsulfotransferase None 
38% (S. sp. SN-
1061M) ADC96650.1 
20 435 Hydroxyphenylglycine Transaminase HpgT 89% (A. orientalis) CAC48367.1 
21 277 BHT Perhydrolase BhtA 91% (A. orientalis) CAA11784.1 
22 588 BHT Peptide Synthetase BhtB 89% (A. orientalis) CAA11773.1 
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Table 9: Predicted ORFs for AB37 Pathway 
Protein length is given in amino acids (AA). 
 
AB 37 ORFs     
ORF 
Length 
(AA) Predicted Gene Product Glycopeptide Homolog AA% ID (Organism) Accession # 
1 202 TetR Family Transcriptional Regulator None 62%(K. flavida) ZP_03865120 
2 229 Short Chain Oxidoreductase None 82%(K. flavida) ZP_03863529  
3 291 Phytanoyl CoA Dioxygenase None 43%(M. carbonacea) ZP_04605278 
4 217 D-ala-D-ala Peptidase VanX 
85%(A. 
teichomyceticus) CAE53345 
5 346 D-ala-D-lac Ligase VanA 
86%(A. 
teichomyceticus) CAE53344  
6 347 D-lactate Dehydrogenase VanH 
85%(A. 
teichomyceticus) CAE53343 
7 430 D-ala-D-ala Carboxypeptidase 
DalaDala 
Carboxypeptidase 65%(A. balhimycina) CAG25753 
8 74 Two-Component Regulatory System VanR 63% (A. balhimycina) CAG25752 
9 387 Two-Component Regulatory System VanS 
72%(A. 
teichomyceticus) CAE53347 
10 146 N-acetyltransferase None 38%(B. cepacia) YP_368498   
11 448 
UDP-N-acetylmuramoyltripeptide D-ala-Dala 
Ligase MurF 
78%(A. 
teichomyceticus) CAE53342  
12 369 DalaDala Ligase None 62%(T. fusca YX) YP_289698  
13 370 UDP-glucosaminyltransferase None 88%(K. flavida) ZP_03862660 
14 396 Ferredoxin Reductase None 71%(S. avermitilis) NP_822785 
15 348 C/O-Methyltransferase None 48%(S. ghanaensis) ZP_04690473 
16 2085 Nonribosomal Peptide Synthetase, modules 1-2 NRPS 1+ 2 
79%(A. 
teichomyceticus) CAE53350 
17 1482 Nonribosomal Peptide Synthetase, module 3 NRPS3 
83%(A. 
teichomyceticus) CAE53351 
18 4075 Nonribosomal Peptide Synthetase, modules 4-6 NRPS 4-6 
82%(A. 
teichomyceticus) CAE53352 
19 1850 Nonribosomal Peptide Synthetase, module 7 NRPS 7 
86%(A. 
teichomyceticus)  CAE53353 
20 491 NDP-Hexose-2,3-Dehydratase EvaA 56%(A. balhimycina) CAC48374 
21 357 Glucose Thymidyltransferase 
Glucose 
Thymidyltransferase 69%(S. sviceus) YP_002205669 
22 378 Glycosyltransferase GtfA 
65%(A. 
teichomyceticus) CAE53349  
23 407 Glycosyltransferase GtfB 
72%(A. 
teichomyceticus) CAE53364 
24 572 Mannosyltransferase MtfA 
77%(A. 
teichomyceticus) CAE53356 
25 629 ABC Transporter ABC transporter 
83%(A. 
teichomyceticus) CAE53357 
26 392 P450 Monooxygenase OxyA OxyA 
88%(A. 
teichomyceticus) CAE53359  
27 385 P450 Monooxygenase OxyB OxyB 
86%(A. 
teichomyceticus) CAE53360 
28 399 P450 Monooxygenase OxyD OxyD 
86%(A. 
teichomyceticus)  CAE53361 
29 411 P450 Monooxygenase OxyC OxyC 
87%(A. 
teichomyceticus) CAE53363 
30 441 Halogenase Halogenase 
69%(A. 
teichomyceticus) CAE53362 
31 507 Non-heme Iron Dioxygenase 
Non-heme Iron 
dioxygenase 
93%(A. 
teichomyceticus) CAE53366 
32 356 DAHP Synthase DAHP synthase 
90%(A. 
teichomyceticus) CAE53368 
33 331 Str Family Transcriptional Regulator Transcriptional Regulator 
83%(A. 
teichomyceticus) CAE53369 
34 230 Response Regulator Res. Regulator (2 comp) 
88%(A. 
teichomyceticus) CAE53348 
35 836 LuxR Regulator LuxR (2 comp) 
78%(A. 
teichomyceticus)  CAE53370 
36 368 Dihydroxyphenylacetic Acid Synthase DpgA 
93%(A. 
teichomyceticus) CAE53371 
37 222 Enoyl-CoA Hydratase/Isomerase DpgB 
84%(A. 
teichomyceticus) CAE53372 
38 434 Dihydroxyphenylacetyl-CoA Oxygenase DpgC 
88%(A. 
teichomyceticus) CAE53373 
39 239 Enoyl-CoA Hydratase/Isomerase DpgD 
91%(A. 
teichomyceticus) CAE53374  
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40 199 GTP Cyclohydrolase GTP Cyclohydrolase 
91%(A. 
teichomyceticus) CAE53376  
41 420 Hydroxyphenylglycine Transaminase HpgT 
89%(A. 
teichomyceticus) CAE53377 
42 374 Prephenate Dehydrogenase 
Prephenate 
Dehydrogenase 
83%(A. 
teichomyceticus) CAG15036 
43 301 Transcriptional Regulator None 50%(S. kasugaensis) BAC53615 
44 329 Transcriptional Regulator None 50%(S. griseus) YP_001827443 
45 522 Non-heme Iron Dioxygenase 
Non-heme Iron 
Dioxygenase 
70%(A. 
teichomyceticus) CAG15037 
46 352 Hydroxymandelate Synthase HmaS 
92%(A. 
teichomyceticus) CAE53378 
47 365 Hydroxymandelate Oxygenase Hmo 
87%(A. 
teichomyceticus) CAE53379  
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Table 10: Predicted ORFs for AB878 Pathway 
Protein length is given in amino acids (AA). 
 
AB878 ORFs      
ORF Length (AA) Predicted Gene Product Glycopeptide Homolog AA %ID (Organism) Accession # 
1 350 D-lactate Dehydrogenase VanH 
74% (A. 
teichomyceticus) CAG15002 
2 346 D-ala-D-lac Ligase VanA 
77% (A. 
teichomyceticus) CAE53344 
3 203 D-ala-D-ala Dipeptidase VanX 
81% (A. 
teichomyceticus) CAE53345 
4 344 Two-Component Regulatory System VanR 69% (S. toyocaensis) AAM80542  
5 224 Two-Component Regulatory System VanS 90% (S. toyocaensis) AAM80541 
6 161 D-ala-D-ala Carboxypeptidase VanY 73% (A. balhimycina) CAG25753 
7 322 Str Family Transcriptional Regulator Trans Reg 85% (A. balhimycina) CAG25754 
8 358 Prephenate Dehydrogenase 
Prephenate 
Dehydrogenase 83% (A. balhimycina) CAG25755 
9 709 ABC Transporter ABC 
81% (A. 
teichomyceticus) CAE53357 
10 1858 Nonribosomal Peptide Synthetase, modules 1-2 NRPS 1-2 77% (A. orientalis) CAA11794 
11 1058 Nonribosomal Peptide Synthetase, modules 3 NRPS 3 
80% (A. 
teichomyceticus) CAE53351 
12 4078 Nonribosomal Peptide Synthetase, modules 4-6 NRPS 4-6 84% (A. orientalis) CAA11795 
13 1835 Nonribosomal Peptide Synthetase, modules 7 NRPS 7 87% (A. orientalis) CAA11796 
14 364 P450 Monooxygenase OxyA OxyA 
81% (A. 
teichomyceticus) CAE53359 
15 386 P450 Monooxygenase OxyB OxyB 
78% (A. 
teichomyceticus) CAE53360 
16 356 P450 Monooxygenase OxyD OxyD 86% (A. orientalis) CAA11798 
17 346 DAHP Synthase DAHP Synthase 
72% (A. 
teichomyceticus) CAE53368 
18 411 P450 Monooxygenase OxyC OxyC 
81% (A. 
teichomyceticus) CAG15021 
19 492 Halogenase Halogenase 93% (A. orientalis) CAA11780 
20 388 Glycosyltransferase GtfA 70% (A. orientalis) AAB49292 
21 409 Glycosyltransferase GtfB 76% (A. orientalis) AAB49293 
22 407 Glycosyltransferase GtfC 72% (A. orientalis) AAB49294 
23 278 Methyltransferase None 54% (S. coelicolor) NP_628799 
24 385 Glycosyltransferase GtfA 
69% (A. 
teichomyceticus) CAE53349 
25 286 Deacetylase Deacetylase 
71% (A. 
teichomyceticus) CAE53355 
26 577 Mannosyltransferase Mannosyltransferase 
79% (A. 
teichomyceticus) CAE53356 
27 347 C/O-Methyltransferase None 51% (S. ghanaensis) ZP_04690473 
28 435 Phenylglycine Aminotransferase HpgT 89% (A. balhimycina) CAC48367 
29 277 BHT Perhydrolase BhtA 92% (A. orientalis) CAA11784 
30 581 BHT Peptide Synthetase BhtB 92% (A. orientalis) CAA11773 
31 397 BHT Oxygenase BhtC 89% (A. orientalis) CAA11772 
32 354 Hydroxymandelate Synthase HmaS 82% (A. orientalis) CAA11761 
33 359 Hydroxymandelate Oxidase Hmo 88% (A. orientalis) CAA11762 
34 456 Na+/H+ Antiporter Putative Antiporter 85% (A. balhimycina) CAC48373 
35 477 NDP-Hexose-2,3-Dehydratase EvaA 90% (A. balhimycina) CAC48374 
36 326 NDP-Hexose-4-Ketoreductase EvaD 86% (A. orientalis) CAA11764 
37 370 NDP-Hexose-3-Aminotransferase EvaB 91% (A. orientalis) CAA11782 
38 206 NDP-Hexose-3,5-Epimerase EvaE 82% (A. orientalis) CAA11781 
39 608 Mannosyltransferase None 64% (S. avermitilis) NP_822291 
40 373 Dihydroxyphenylacetic Acid Synthase DpgA 94% (A. orientalis) CAA11765 
41 219 Enoyl-CoA Hydratase/Isomerase DpgB 85% (A. balhimycina) CAC48379 
42 379 Dihydroxyphenylacetyl-CoA Oxygenase DpgC 87% (A. orientalis) CAA11787 
43 268 Enoyl-CoA Hydratase/Isomerase DpgD 89% (A. balhimycina) CAC48381 
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Table 11: Predicted ORFs for AB915 Pathway 
Protein length is given in amino acids (AA). 
 
AB915 ORFs     
ORF Length (AA) Predicted Gene Product Glycopeptide Homolog AA %ID (Organism) Accession # 
1 330 D-ala-D-ala Ligase None 61% (T. fusca YX) YP_289698 
2 214 D-ala-D-ala Dipeptidase VanX 81% (A. teichomyceticus) CAE53345 
3 347 D-ala-D-lac-Ligase VanA 79% (A. teichomyceticus) CAE53344 
4 419 Betalactamase None 51% (A. mirum) ZP_03818051 
5 277 Phytanoyl CoA Dioxygenase None 46%(M. carbonacea) ZP_04605278 
6 448 
UDP-N-acetylmuramoyltripeptide-D-ala-
D-ala Ligase MurF 75% (A. teichomyceticus) CAE53342  
7 333 D-lactate Dehydrogenase VanH 70% (A. teichomyceticus) CAG15002 
8 399 Two-component Regulatory System VanS 
67% (Frankia sp. 
EAN1pec) YP_001511361 
9 230 Two-component Regulatory System VanR 87% (S. toyocaensis) AAM80541 
10 206 D-ala-D-ala Carboxypeptidase VanY 54% (S. nassauensis) ZP_04486505 
11 368 C/O-Methyltransferase None 50% (S. ghanaensis) ZP_04690473 
12 1054 
Nonribosomal Peptide Synthetase Module 
1 NRPS1 75% (S. toyocaensis) AAM80539 
13 1106 
Nonribosomal Peptide Synthetase Module 
2 NRPS2 76% (A. teichomyceticus) CAE53350 
14 1060 
Nonribosomal Peptide Synthetase Module 
3 NRPS3 77% (A. teichomyceticus) CAE53351 
15 4068 
Nonribosomal Peptide Synthetase Modules 
4-6 NRPS4-6 78% (A. teichomyceticus) CAE53352 
16 1872 
Nonribosomal Peptide Synthetase Module 
7 NRPS7 83% (A. teichomyceticus) CAE53353 
17 501 NDP-Hexose-2,3-Dehydratase EvaA 66% (S. cyanogenus)  AAD13549 
18 357 Glucose Thymidylyltransferase 
Glucose 
Thymidylyltransferase 70% (S. sviceus) YP_002205669 
19 375 Glycosyltransferase 
GtfA 
(glycosyltransferase) 61% (A. orientalis) AAB49292 
20 408 Glycosyltransferase 
GtfB 
(glycosyltransferase) 70% (Nonomuraea sp.) CAD91204 
22 407 Glycosyltransferase 
GtfC 
(glycosyltransferase) 67% (A. orientalis) AAB49294 
21 274 Methyltransferase Type 11 None 
57% (Frankia sp. 
EAN1pec) YP_001508433 
23 381 Glycosyltransferase 
GtfA 
(glycosyltransferase) 63% (A. teichomyceticus) AAB49294 
24 374 NDP-Hexose-3-Aminotransferase EvaB  80% (S. arenicola) YP_001537186 
25 201 NDP-Hexose-3,5-Epimerase EvaD 68% (S. arenicola) YP_001537187 
26 334 NDP-Hexose-4-Ketoreductase EvaE 69% (S. arenicola) YP_001537188 
27 238 Methyltransferase Type 12 None 74% (S. arenicola) YP_001539299 
28 579 Mannosyltransferase Mannosyltransferase 71% (A. teichomyceticus) CAE53356 
29 659 ABC Transporter ABC Transporter 81% (A. teichomyceticus) CAE53357 
30 231 Str Family Transcriptional Regulator None 42% (S. griseus) YP_001822146 
31 392 P450 Monooxygenase, OxyA OxyA 84% (A. teichomyceticus) CAE53359 
32 385 P450 Monooxygenase, OxyD OxyD 80% (A. teichomyceticus) CAE53360 
33 399 P450 Monooxygenase, OxyB OxyB 78% (A. teichomyceticus) CAE53361 
34 411 P450 Monooxygenase, OxyC OxyC 86% (A. teichomyceticus) CAE53363 
35 412 Halogenase Halogenase 66% (A. teichomyceticus) CAE53362 
36 531 Non-Heme Iron Dioxygenase 
Non-Heme Iron 
Dioxygenase 84% (A. teichomyceticus) CAE53366 
37 352 DAHP Synthase DAHP Synthase 87% (A. teichomcyeticus) CAE53368 
38 339 Str Family Transcriptional Regulator Str Family Trans Reg 77% (A. teichomyceticus) CAE53369 
39 513 Non-Heme Iron Dioxygenase iron dioxygenase 56% (S. toyocaensis) AAM80528 
40 389 Hydroxymandelate Oxygenase Hmo 70% (S. toyocaensis) AAM80552 
41 806 Transcriptional Regulator trans regulator 58% (A. teichomyceticus) CAE53370 
42 199 GTP Cylcohydrolase GTP Cyclohydrolase 92% (A. teichomyceticus) CAE53376 
43 420 Hydroxyphenylglycine Transaminase HpgT 88% (A. teichomyceticus) CAG15035 
44 122 Chorismate Mutase None 68% (N. dassonvillei) ZP_04335576 
45 354 Hydroxymandelate Synthetase HmaS 64% (Frankia sp. CcI3) YP_481550 
46 365 Prephenate Dehydrogenase 
Prephenate 
Dehydrogenase 73% (A. teichomyceticus) CAG15036 
47 369 Dihydroxyphenylacetic Acid Synthase DpgA 84% (A. teichomyceticus) CAE53371 
48 221 Enoyl-CoA Hydratase/Isomerase DpgB 67% (A. teichomyceticus) CAE53372 
49 434 Dihydroxyphenylacetyl-CoA Oxygenase DpgC 78% (A. teichomyceticus) CAE53373 
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50 239 Enoyl-CoA Hydratase/Isomerase DpgD 83% (A. teichomyceticus) CAE53374 
51 395 UDP muramoyl pentapeptide transferase MurG 60% (S. arenicola) YP_001535200 
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Table 12: Predicted ORFs for the AZ205 Pathway 
Protein length is given in amino acids (AA). 
 
AZ205 ORFs     
ORF Length (AA) Predicted Gene Product Glycopeptide Homolog AA% ID (Organism) Accession # 
1 184 VanY-Carboxypeptidase VanY 78%(Nonomuraea sp.) CAD91202.1 
2 232 Two-Component Regulatory System VanR 91%(Nocardia farcinica) BAD55538.1 
3 374 Two-Component Regulatory System VanS 77%(Nocardia farcinica) BAD55539.1 
4 446 
UDP-N-acetylmuramoyltripeptide-D-ala-D-ala 
Ligase MurF 80% (A. teichomyceticus) CAE53342.1 
5 169 Transposase None 57% (S. erythraea) CAM04227.1 
6 344 D-lactate Dehydrogenase VanH 76% (A. orientalis) AEI58859.1 
7 347 D-ala-D-lac-Ligase VanA 76% (A. teichomyceticus) CAE53344.1 
8 203 D-ala-D-ala Dipeptidase VanX 79% (A. teichomyceticus) CAE53345.1 
9 226 Hypothetical Protein None 43% (C. michiganensis) CAN02774.1 
10 222 Transposase None 54% (Frankia alni) CAJ61201.1 
11 384 Methyltransferase None 
43% (Nodularia 
spumigena) EAW44464.1 
12 653 ABC Transporter ABC Transporter 94% (A. orientalis) AEI58864.1 
13 3151 Nonribosomal Peptide Synthetase Module 1-3 NRPS1-3 71% (A. orientalis) CAA11794.1 
14 4112 Nonribosomal Peptide Synthetase Modules 4-6 NRPS4-6 81% (A. orientalis) CAA11795.1 
15 1864 Nonribosomal Peptide Synthetase Module 7 NRPS7 84% (A. orientalis) CAA11796.1 
16 494 P450 Monooxygenase, OxyA OxyA 74% (A. orientalis) AEI58868.1 
17 356 P450 Monooxygenase, OxyB OxyB 89% (A. orientalis) CAA11798.1 
18 278 Sulfotransferase StaL 51% (S. toyocaensis) AAM80529.1 
19 442 P450 Monooxygenase, OxyC OxyC 80% (A. balhimycina) CAA76549.1 
20 493 Halogenase Halogenase 89% (A. balhimycina) CAA76550.1 
21 409 Glycosyltransferase Glycosyltransferase 81% (A. balhimycina) CAA76552.1 
22 275 Deacetylase Deacetylase 63% (A. teichomyceticus) CAE53355.1 
23 274 N-methyltransferase N-methyltransferase 70% (A. orientalis) CAA11779.1 
24 429 Hydroxyphenylglycine Transaminase HpgT 89% (A. orientalis) CAA11790.1 
25 277 BHT Perhydrolase BhtA 87% (A. orientalis) CAA11784.1 
26 579 BHT Peptide Synthetase BhtB 84% (A. orientalis) CAA11773.1 
27 400 BHT Oxygenase BhtC 88% (A. orientalis) CAA11772.1 
28 361 Hydroxymandelate Synthase HmaS 80% (A. balhimycina) CAC48371.1 
29 359 Hydroxymandelate Oxidase Hmo 81% (A. orientalis) CAA11762.1 
30 373 Dihydroxyphenylacetic Acid Synthase DpgA 92% (A. orientalis) CAA11765.1 
31 225 Enoyl-CoA Hydratase/Isomerase DpgB 84% (A. balhimycina) CAC48379.1 
32 433 Dihydroxyphenylacetyl-CoA Oxygenase DpgC 70% (A. balhimycina) CAC48380.1 
33 447 Antiporter None 43% (B. thuringiensis) ADY24350.1 
34 389 femAB protein StaO 88% (S. toyocaensis) AAM80555.1 
35 469 Prephenate Dehydrogenase 
Prephenate 
Dehydrogenase 53% (A. orientalis) AEI58863.1 
36 259 Thioesterase None 
66% (Streptomyces sp. 
CS) ADM46371.1 
37 239 Methyltransferase None 66% (S. flavogriseus) ADW05446.1 
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Figure 20: ESI-MS/MS fragmentation data for sulfo-teicoplanin aglycone A (20). 
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Figure 21: 1H NMR of sulfo-teicoplanin aglycone A (20) in d6-DMF at 323 K 
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Figure 22: 1H - 1H Correlation Spectroscopy (COSY) NMR of sulfo-teicoplanin 
aglycone A (20) in d6-DMF at 323 K 
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Figure 23: ESI-MS/MS fragmentation data for sulfo-teicoplanin aglycone B (21) 
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Figure 24: 1H NMR of sulfo-teicoplanin aglycone B (21) in d6-DMF at 323 K 
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Figure 25: 1H - 1H Correlation Spectroscopy (COSY) NMR of sulfo-teicoplanin 
aglycone B (21) in d6-DMF at 323 K 
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Figure 26: ESI-MS/MS fragmentation data for sulfo-teicoplanin aglycone C (22) 
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Figure 27: 1H NMR of sulfo-teicoplanin aglycone C (22) in d6-DMF at 323 K 
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Figure 28: 1H - 1H Correlation Spectroscopy (COSY) NMR of sulfo-teicoplanin 
aglycone C (22) in d6-DMF at 323 K 
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Figure 29: ESI-MS/MS fragmentation data for teicoplanin aglycone 
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Figure 30: 1H NMR of teicoplanin aglycone in d6-DMF at 323 K 
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Figure 31: 1H - 1H Correlation Spectroscopy (COSY) NMR of teicoplanin aglycone in 
d6-DMF at 323 K 
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Figure 32: Numbering scheme for teicoplanin aglycone and derivatives 
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Table 13: 1H NMR chemical shift data for sulfo-teicoplanin aglycone A (20) 
  Sulfo-teicoplanin aglycone A 323K in d6-DMF     
   δ (ppm) Multiplicity, J Coupling COSY (strong) COSY (weak) 
1b 6.8 d, J = 2.7 Hz   
1e 6.91 d, J = 9.1 Hz 7.04  
1f 7.04 m 6.91  
2b 7.31 d, J = 1.7 Hz  7.78 
2e 7.13 d, J = 8.2 Hz 7.78  
2f 7.78 dd, J = 1.7, 8.3 Hz 7.13 7.31 
3b 7 t, J = 2.1 Hz  6.77, 6.81 
3d 6.81 bs  6.81 
3f 6.77 m  7 
4b 5.68 m  5.3 
4f 5.3 s  5.68 
5b 7.07 m  6.74 
5e 6.74 d, J = 8.5 Hz   
5f 6.77 bs   
6b 7.9 d, J = 1.9 Hz  7.6 
6e 7.34 d, J = 8.3 Hz 7.6  
6f 7.6 m 7.34  
7d 6.61 d, J = 2.5 Hz  6.47 
7f 6.47 m  6.61 
w1 ND    
w2 7.6 m 5.09  
w3 8.1 m 5.56  
w4 7.13 d, J = 8.2 Hz 5.68  
w5 8.31 m 4.47  
w6 6.47 m 4.36  
w7 8.31 m 4.69  
x1 4.69 m   
x2 5.09 m 7.6 2.95, 3.39 
x3 5.56 d, J = 10.5 Hz 8.1  
x4 5.68 m 7.13  
x5 4.47 d, J = 5.1 Hz 8.31  
x6 4.36 d, J = 12.1 Hz 6.47  
x7 4.69 m 8.31  
z2 2.95 Under Solvent 3.39 5.09 
z2' 3.39 dd, J = 5.4, 13.8 Hz 2.95 5.09 
z6 5.4 s 4.36   
 
138 
 
 
Table 14: 1H NMR chemical shift data for sulfo-teicoplanin aglycone B (21) 
  Sulfo-teicoplanin aglycone B 323K in d6-DMF     
   δ(ppm) Multiplicity, J Coupling COSY (strong) COSY (weak) 
1b 6.77 m   
1e 6.92 d, J = 8.3 Hz 7.05  
1f 7.05 m 6.92  
2b 7.3 d, J = 1.7 Hz   
2e 7.14 d, J = 8.3 Hz 7.73  
2f 7.73 dd, J = 1.8, 8.4 Hz 7.14  
3b 6.52 m   
3d 6.35 t, J = 2.1 Hz  6.58 
3f 6.58 bs  6.35 
4b 5.68 m  5.29 
4f 5.29 bs  5.68 
5b 7.05 m   
5e 6.71 d, J = 8.5 Hz 6.77  
5f 6.77 m 6.71  
6b 7.9 s   
6e 7.26 d, J = 8.5 Hz 7.6  
6f 7.6 dd, J = 1.5, 8.5 Hz 7.26  
7d 6.57 bs  6.43 
7f 6.43 s  6.57 
w1 ND    
w2 7.56 d, J = 8.9 Hz 5.08  
w3 8.07 d, J = 10.4 Hz 5.52  
w4 7.05 m 5.68  
w5 8.28 m 4.47  
w6 6.52 m 4.41  
w7 8.28 m 4.68  
x1 4.7 s   
x2 5.08 m 7.56 2.98, 3.39 
x3 5.52 d, J = 10.5 Hz 8.07  
x4 5.68 m 7.05  
x5 4.47 d, J = 4.7 Hz 8.28  
x6 4.41 d, J = 12.1 Hz 6.92  
x7 4.68 bs 8.28  
z2 2.98 Under Solvent 3.39 5.08 
z2' 3.39 dd, J = 5.5, 13.9 Hz 2.98 5.08 
z6 5.97 s     
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Table 15: 1H NMR chemical shift data for sulfo-teicoplanin aglycone C (22) 
  Sulfo-teicoplanin aglycone C 323K in d6-DMF     
  δ(ppm) Multiplicity, J Coupling COSY (strong)  COSY (weak) 
1b 6.72 d, J = 1.8 Hz  7.02 
1e 6.89 d, J = 8.4 Hz 7.02  
1f 7.02 dd, J = 1.8, 8.4 Hz 6.89 7.02 
2b 7.22 m  7.62 
2e 7.55 d, J = 8.6 Hz 7.62  
2f 7.62 dd, J = 1.8, 8.6 Hz 7.55 7.22 
3b 6.41 bs  6.34 
3d 6.34 t, J = 2.2 Hz  6.41, 6.60 
3f 6.6 d, J = 2.2 Hz  6.34 
4b 5.81 d, J = 1.4 Hz   
4f 5.18 bs   
5b 7.07 m  6.81 
5e 6.74 d, J = 8.4 Hz 6.81  
5f 6.81 dd, J = 2.2, 8.4 Hz 6.74 7.07 
6b 7.89 d, J = 2.0 Hz  7.52 
6e 7.22 m   
6f 7.52 dd, J = 1.5, 8.6 Hz 7.89  
7d 6.59 bs  6.48 
7f 6.48 d, J = 2.1 Hz  6.59 
w1 ND    
w2 7.49 d, J = 8.9 Hz 5.07  
w3 7.97 d, J = 11.1 Hz 5.46  
w4 7.07 m 5.66  
w5 8.26 d, J = 5.0 Hz 4.5  
w6 6.44 d, J = 12.2 Hz 4.36  
w7 8.36 d, J = 6.0 Hz 4.68  
x1 4.68 m   
x2 5.07 m 7.49 2.98, 3.38 
x3 5.46 d, J = 10.6 Hz 7.97  
x4 5.66 d, J = 8.1 Hz 7.07  
x5 4.5 d, J = 5.2 Hz 8.26  
x6 4.36 d, J = 12.2 Hz 6.44  
x7 4.68 m 8.36  
z2 2.98 Under Solvent 3.38 5.07 
z2' 3.38 dd, J = 5.5, 13.9 Hz  2.98 5.07 
z6 5.38 bs     
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Table 16: 1H NMR chemical shift data for teicoplanin aglycone 
  Teicoplanin aglycone 323K in d6-DMF   
   δ (ppm) Multiplicity, J Coupling COSY (strong) COSY (weak) 
1b 6.83 d, J = 1.7 Hz   
1e 6.96 d, J = 8.3 Hz 7.12  
1f 7.12 m 6.96  
2b 7.29 d, J = 1.9 Hz   
2e 7.12 m 7.79  
2f 7.79 dd, J = 1.6, 8.4 Hz 7.12  
3b 6.43 bs   
3d 6.3 t, J = 2.1 Hz   
3f 6.62 d, J = 2.4 Hz   
4b 5.68 m  5.28 
4f 5.28 d, J = 1.4 Hz  5.68 
5b 7.07 d, J = 2.3 Hz   
5e 6.73 d, J = 8.5 Hz   
5f 6.79 dd, J  2.3, 8.3 Hz   
6b 7.9 d, J = 2.0 Hz  7.6 
6e 7.32 d, J = 8.5 Hz 7.6  
6f 7.6 dd, J = 1.9, 8.3 Hz 7.32 7.9 
7d 6.6 s   
7f 6.46 d, J = 2.4 Hz   
w1 ND    
w2 7.92 d, J = 9.6 Hz 5.06  
w3 8.11 d, J = 10.9 Hz 5.53  
w4 7.11 m 5.68  
w5 8.27 d, J = 5.2 Hz 4.48  
w6 6.5 m 4.36  
w7 8.32 d, J = 6.1 Hz 4.71  
x1 5.13 d, J = 4.5 Hz   
x2 5.06 m 7.92 2.98, 3.40 
x3 5.53 d, J = 10.3 Hz 8.11  
x4 5.68 m 7.11  
x5 4.48 d, J = 5.3 Hz 8.27  
x6 4.36 d, J = 12.1 Hz 6.5  
x7 4.71 d, J = 6.0 Hz 8.32  
z2 2.98 dd, J = 3.2, 14.2 Hz 3.4 5.06 
z2' 3.4 dd, J = 5.4, 14.2 Hz 2.98 5.06 
z6 5.41 bs     
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Table 17: 1H NMR data for A47934 and derivatives produced in vivo 
  
δ (ppm) 
Compound 
28 
δ (ppm) 
Compound 
29  
δ (ppm) 
Compound 
30 
δ (ppm) 
Compound 
31 
δ (ppm) 
Compound 
32 
1b 7.01 7.02 7.00 7.02 6.97 
1e 7.61 7.60 7.65 7.61 7.61 
1f 7.38 7.35 7.38 7.38 7.33 
2b 7.32 7.31 7.32 7.33 7.31 
2e 7.21 7.19 7.35 7.22 7.20 
2f 7.58 7.57 7.58 7.63 7.57 
3b 6.49 6.49 6.49 6.50 6.46 
3d 6.62 6.61 6.63 6.62 6.61 
3f 6.24 6.27 6.22 6.26 6.21 
4b 5.27 5.26 5.27 5.30 5.27 
4f 5.68 5.68 5.82 5.70 5.68 
5b 6.96 6.97 6.98 6.97 6.95 
5f 7.01 6.98 7.02 7.01 7.01 
6b 7.60 7.59 7.61 7.60 7.59 
6e 7.21 7.18 7.21 7.21 7.20 
6f 7.47 7.47 7.51 7.47 7.49 
7d 6.52 6.58 6.53 6.52 6.51 
7f 6.44 6.23 6.45 6.44 6.43 
x1 5.40 5.40 5.40 5.40 4.94 
x2 4.94 4.98 4.94 4.94 4.87 
x3 5.49 5.49 5.49 5.49 5.43 
x4 5.49 5.52 5.49 5.49 5.49 
x5 4.35 4.35 4.36 4.36 4.35 
x6 4.00 4.03 4.02 4.02 4.00 
x7 4.53 4.72 4.53 4.53 4.53 
z2 3.35 3.35 3.36 3.34 3.35 
z2' 3.10 3.09 3.11 3.11 3.10 
z6 5.47 5.43 5.48 5.47 5.47 
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Table 18: Compound specific 1H and 13C assignments for compounds 29-32 
The 1H and 13C chemical shifts reported in this table detail the specific chemical shifts used 
to make the structural assignments of compounds 29-32. For compound 29, these are the 
chemical shifts for both the parent compound (Compound 28) and the new compound at the 
C-terminus of the glycopeptide. For compounds 30 and 31, the chemical shifts reported are 
the key shifts vital to the assigning the position of the compound specific modification 
(sulfonation and glycosylation, respectively) of the hydroxyl at the top of ring 4. For 
compound 32, the shifts reported are those new signals and the observed changes in the 13C 
at the C-α, x1, at the N-terminus. 
 
 
 
  Compound 28 Compound 29 
r7 (1H) - 3.85 
r7 (13C) - 53.21 
y7 (13C) 176.79 172.32 
x7 (13C) 59.09 57.11 
   
  Compound 28 Compound 30 
4a (13C) 135.27 138.22 
4b (13C) 107.5 108.93 
4c (13C) 146.53 151.65 
4d (13C) 132.98 128.41 
4e (13C) 147.08 151.84 
4f (13C) 104.16 104.22 
      
  Compound 28 Compound 31 
4a (13C) 135.27 134.29 
4b (13C) 107.5 107.56 
4c (13C) 146.53 151.38 
4d (13C) 132.98 130.95 
4e (13C) 147.08 151.78 
4f (13C) 104.16 104.11 
      
  Compound 28 Compound 32 
4a (13C) 135.27 134.29 
4b (13C) 107.5 107.56 
4c (13C) 146.53 151.38 
4d (13C) 132.98 130.95 
4e (13C) 147.08 151.78 
4f (13C) 104.16 104.11 
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Table 19: Numbering scheme and 1H and 13C assignments for compound 31 - 
glucose 
 
 
 
  1H (ppm)  13C (ppm)  Observed 
3J 
(Guzman-
Martinez, 
Lamer et 
al.)  
b 5.33 104.49 7.8 
c 3.75 73.2 8.6 
e 3.68 75.28 9.5 
g 3.63 68.69 9.5 
i 3.56 76.06 - 
j 3.88 59.98 5.18 
k 3.8 59.98 - 
 
O
O
HO
OH
OH
HO
b
c e
gi
j,k
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Figure 33: 1H of Compound 28, 298K in 3:1 D2O:CD3CN 
 
145 
 
 
Figure 34: 1H-13C HMQC of Compound 28, 298K in 3:1 D2O:CD3CN  
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Figure 35: 1H-13C HMBC of Compound 28, 298K in 3:1 D2O:CD3CN 
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Figure 36: 1H of Compound 29, 298K in 3:1 D2O:CD3CN 
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Figure 37: 1H-13C HMQC of Compound 29, 298K in 3:1 D2O:CD3CN 
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Figure 38: 1H-13C HMBC of Compound 29, 298K in 3:1 D2O:CD3CN 
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Figure 39: 1H of Compound 30, 298K in 3:1 D2O:CD3CN 
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Figure 40: 1H-13C HMQC of Compound 30, 298K in 3:1 D2O:CD3CN 
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Figure 41: 1H-13C HMBC of Compound 30, 298K in 3:1 D2O:CD3CN 
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Figure 42: 1H of Compound 31, 298K in 3:1 D2O:CD3CN 
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Figure 43: 1H-13C HMQC of Compound 31, 298K in 3:1 D2O:CD3CN 
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Figure 44: 1H-13C HMBC of Compound 31, 298K in 3:1 D2O:CD3CN 
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Figure 45: 1H of Compound 31, 313K in 3:1 D2O:CD3CN 
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Figure 46: 1H of Compound 32, 298K in 3:1 D2O:CD3CN 
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Figure 47: 1H-13C HMQC of Compound 32, 298K in 3:1 D2O:CD3CN 
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Figure 48: 1H-13C HMBC of Compound 32, 298K in 3:1 D2O:CD3CN 
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Figure 49: New glycopeptide congeners produced using eDNA-derived tailoring enzymes 
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